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ASSESSMENT OF MOLECULAR ACTION OF DIRECT GATING AND 
ALLOSTERIC MODULATORY EFFECTS OF MEPROBAMATE (MILTOWN®) 
ON GABAA RECEPTORS 
Manish Kumar 
Meprobamate (tradenames Miltown, Equanil) is a schedule IV anxiolytic and the primary 
metabolite of the muscle relaxant carisoprodol.  Meprobamate modulates GABAA (-
aminobutyric acid type A) receptors, and has been described as having barbiturate-like activity.  
A thorough understanding of its mechanism remains ill-defined, however. To gain insight into 
its actions, we have conducted a series of studies using recombinant GABAA receptors. In 
xz GABAA receptors (where x = 1-6 and z = 1-3), the ability to enhance GABA-mediated 
current was evident for all  subunit isoforms, with the largest effect observed in 5-expressing 
receptors. Direct gating was comparable with all  subunits, although the effect was attenuated 
in α3-expressing receptors.  Allosteric potentiating and direct gating effects were comparable 
in 112 and 122 receptors, whereas allosteric effects were enhanced in 12 compared 
to 122 receptors. In “extrasynaptic” GABAA receptors (α1β3δ and α4β3δ receptors), 
meprobamate allosterically enhanced both EC20 and saturating GABA currents, and directly 
activated these receptors with an efficacy comparable to that of GABA.  Bemegride, which 
antagonizes effects of pentobarbital, attenuated direct gating effects of meprobamate.  Whereas 
pentobarbital directly gated homomeric β3 receptors, meprobamate did not, and instead 
blocked the spontaneously open current present in these receptors. In wild type homomeric ρ1 
 
  
receptors, both pentobarbital and meprobamate were ineffective in direct gating; a mutation 
(W328M) previously shown to confer sensitivity to pentobarbital, did not confer sensitivity to 
meprobamate.  Our results provide additional insight into the actions of meprobamate and 
parent therapeutic agents such as Carisoprodol as well as possible domains involved in the 
direct gating actions of the ligands including transmembrane domains TM4. Further, using site-
directed-mutagenesis and whole cell patch clamp electrophysiology in transiently transfected 
HEK293 cells, we examined the role of GABAA receptor α-subunit transmembrane domain 4 
(TM4) and transmembrane domain 2 (TM2) amino acids in direct gating, and inhibitory actions 
of meprobamate. Mutation of α3 valine at position 440 to leucine (present in the equivalent 
position in the α1 subunit) increased the direct gating potency and efficacy of meprobamate. 
In R-α1β2 heteromeric GABAA receptor, both pentobarbital and carisoprodol had inhibitory 
effect for allosteric modulatory action at higher concentrations. Meprobamate did not have an 
inhibitory effect at the concentrations tested. T6’F mutation of the β2-subunit abolished the 
inhibition of carisoprodol but not of pentobarbital. Thus, our studies provide further insight 
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   CHAPTER I 
                                             INTRODUCTION 
MEPROBAMATE 
History 
             Meprobamate was the first drug to be marketed specifically as an anxiolytic drug, that 
is, capable of allaying anxiety and related conditions, without inducing sedation or sleep. 
Development of meprobamate is attributed to some serendipitous observations during the 
course of development of new preservatives, after discovery of penicillin. During the course 
of a search for compound to prevent enzymatic destruction of penicillin by penicillinase 
producing gram-negative bacteria, normally present in the air, a compound mephenesin was 
found to have reversible tranquilizing and muscle relaxing properties (Berger et al., 1946). 
Although later a powder form of penicillin made obsolete the use of preservatives, some 
interesting properties observed with these α-substituted esters of glycerol, created a lot of 
attention. As stated earlier, mephenesin possessed tranquilizing and at high doses, sedative and 
muscle relaxant properties. Initial excitatory effect, associated with barbiturate use was absent, 
showing a lack of central action. For the muscle relaxant properties, diaphragm muscle was 
last to get affected, causing the respiratory paralysis to appear last as a lethal side effect and at 
a very high dose. There was a large gap between dose for paralysis of other muscles and 
diaphragmatic muscle (Berger, 1947). However, curare, a widely used muscle relaxant of the 
day as an adjuvant to anesthetics, had respiratory paralysis as a major side effect (Delahanty et 
al., 2011; Chen et al., 2014). In addition, mephenesin possessed a unique anticonvulsant action. 
Strychnine-induced convulsions (convulsions induced via actions at spinal cord) were inhibited 
by tranquilizing doses of mephenesin while hexobarbitone, a barbiturate, was unable to prevent 




inhibited by hexobarbitone, but required a very high dose of mephenesin. Above effects show 
the effect of mephenesin at spinal cord level rather than at the midbrain level. This also 
explained the initial missing euphoric and exciting action associated with the use of 
mephenesin (associated with a central action), present with the use of barbiturates. However, 
its use as such was limited by its three major drawbacks—mephenesin was quickly metabolized 
to inactive products leading to a very short duration of action, greater effect on the spinal cord 
than on supra-spinal structures and a weak action, so large doses were required (Berger, 1947).  
Mephenesin was quickly metabolized via oxidation of its terminal hydroxyl group leading to 
the formation of inactive metabolites. Blocking the oxidation of the terminal hydroxyl group 
would be a major mechanism for extended action of mephenesin. After some trial and error, 
carbamate esters of 1, 3-propane diols were prepared which had longer duration of action and 
stronger muscle relaxant properties. By the late 1950s meprobamate was the most widely 
prescribed drug in the United States and in many other countries. It retained its lead until 
diazepam, the second drug from the benzodiazepine series, was introduced into clinical use in 
late 1960 (Greenblatt et al., 1974). 
             Within 2 years of introduction of meprobamate, cases of its abuse and withdrawal after 
long term use were reported (Boyd et al., 1958). By 1970 it was listed as a controlled substance, 
in USA market, after it was discovered to cause physical and psychological dependence. While 
meprobamate was made a controlled substance, drugs metabolized to meprobamate are widely 
used and abused and are associated with serious side effects. One such drug carisoprodol, 























Chemistry and Physiological Effects of Meprobamate 
             Meprobamate (Miltown by wallace laboratories and Equanil by Wyeth Laboratories), 
chemically, is 2-methyl-2-npropyl- 1, 3-propanediol dicarbamate. First synthesized in 1950 by 
Ludwig and Piech (1951), meprobamate has the following physical properties: It is a white 
crystalline powder with a characteristic bitter taste and faint odor. It melts without 
decomposition at 104-106°C. It is soluble in water to the extent of 0.34 per cent at 20°C and 
0.79 per cent at 37°C, but is readily soluble in most organic solvents. It is unaffected by dilute 
acid and alkali and thus is not broken down in gastric or intestinal juices (Berger, 1954). 
             Meprobamate when applied to mice, lead to a sedative action accompanied by loss of 
righting reflex. Unlike barbiturates, loss of righting reflex associated with the use of 
meprobamate is unaccompanied by any sign of excitability. Common signs of excitability like 
aimless running, arching and stretching of back and hind limbs, licking of paws, are present 
during induction of barbiturates, while absent even at paralyzing doses of meprobamate. 
Recovery is spontaneous and complete. Although mephenesin too had similar anesthetic 
action, meprobamate had longer periods of induction and duration and is also effective orally 
(Berger, 1954). 
             Monkeys exposed to 200 mg/kg meprobamate, calmed down and became easier to 
control. They became easier to pet and easily had their food. There were no signs of agitation 
or excitement. This stage lasted for 5-6 hours. At 400 mg/kg dose, there was a complete flaccid 
paralysis that lasted for 7 hours. At higher doses there was longer duration of action. Even at 
these higher doses respiration and heart beat were normal and the monkeys recovered almost 




             Dogs exposed to high dose of meprobamate for a long duration (sub-acute, 60-75 
days), did not show any hematological abnormality or abnormalities in kidney function tests. 
Autopsy reports also did not show ill effects in viscera of kidney, liver, stomach, small 
intestine, bladder or adrenal glands. Mice exposed to very high doses for a very long time 
period (chronic, 12-15 months) also did not show signs of toxicity, except for decreased weight 
gain (Berger, 1954). 
             Meprobamate was also effective in preventing pentylenetetrazole, strychnine and 
electroshock mediated convulsions and death in mice (Berger, 1954). 
             A search for separation of muscle relaxant properties of meprobamate with its 
tranquilizing properties led to invention of N-isopropyl-2-methyl-npropyl-1,3-propanediol 
dicarbamate or carisoprodol which differed from meprobamate in having an iso-propyl group 
in place of hydrogen atom in one of the carbomyl nitrogens (Berger 1959). Although minor, 
the difference in structure produced surprisingly different pharmacological and functional 
properties in carisoprodol. 
             In electro encephalic recordings in cats and rabbits, meprobamate did not have any 
effect in brain wave patterns (Gangloff, 1959). Carisoprodol in similar doses, produced an 
increase in amplitude and a decrease in frequency in the cortical and sub cortical regions 
(Berger et al., 1960). The characteristic spindling of electro encephalic recordings of 
barbiturates was also missing with that of both carisoprodol and meprobamate. Larger doses 
of carisoprodol caused a progressive slowing of frequency and an increase in amplitude until 
40-60mg/kg dose. Still higher doses caused greatly reduced activity and longer stretches of 
electric silence (Berger et al., 1960). A remarkable property of carisoprodol, at lower doses (5 




behavioral changes. In this respect carisoprodol resembled atropine, the anti-cholinergic agent, 
which also made changes in the brain wave pattern unaccompanied by behavioral changes 
(Longo, 1956; Bradley et al., 1957). However at higher doses, while carisoprodol caused 
muscle relaxation, paralysis and a generalized central nervous system depression, atropine lead 
to an excitement. On account of the above similarity, when carisoprodol was explored for 
peripheral anticholinergic actions, it was found to have none. Convulsions by convulsive 
discharges set up in limbic system by electric stimulation, were prevented by meprobamate, 
mephenesin and barbiturates, but not by carisoprodol. This was a strange finding considering 
more similarity in the structure of meprobamate and carisoprodol compared to meprobamate 
and mephenesin. This lack of action of carisoprodol in the limbic system fits with clinical 
finding of lack of tranquilising action with carisorpodol (Berger et al., 1960). 
Felbamate 
 
              Felabamte (2-phenyl-1,3-propanediol dicarbamate) was prescribed as an anti-epileptic 
drug prescribed in adult (Absence seizure), and childhood epilepsy (Lenaux-Gastaut 
syndrome). However, fatal cases of aplastic anemia and hepatotoxicity has precluded its use as 




Lenaux-gastaut syndrome. However recent clinical trials have shown it to be safe, well 
tolerated and effective in various types of epilepsy syndromes (Shah et al., 2016). 
              Felbamate has been known to act via activation of GABAA receptor and inhibition of 
NMDA receptors. The dual mechanism of action has been responsible for the broad spectrum 
anti-epileptic action (Rho et al., 1994). Meprobamate has also been known to have similar 
action on GABAA and NMDA receptors. But while meprobamate both directly gate and 
allosterically modulate GABAA receptors, felbamate has just direct gating action on GABAA 
receptor (Rho et al., 1997). Clinically, while felbamate is mildly sedating, broad spectrum 
antiepileptic agent, meprobamate has been shown to have a strong tranquilizing, sedating but 
weak anti-epileptic effect (Rho et al., 1997). A detailed subunit dependent effect of felbamate 
may explain the molecular basis for the differences in the clinical effects of the two drugs. 
      
             Most severe side effects of felbamate include aplastic anaemia and severe 
hepatotoxicity. Others include nausea, vomiting, insomnia, anorexia, dizziness and headache.  
Pharmacology and Metabolism of Meprobamate 
             Meprobamate is used either alone or in combination with other common over-the-
counter drugs like, diphenhydramine, acetylsalicylic acid or codeine. Meprobamate 
pharmacokinetics are unaffected by these commonly used combinations. However, 
diphenhydramine metabolism is affected by meprobamate. Bioavailability is similar for oral or 
rectal application (Gilbert et al., 1984). 
             After oral ingestion of a therapeutic dose, most of meprobamate is absorbed via GI 




meprobamate was found in the feces (showing maximum absorption via GI tract). In studies 
using carbon labelled meprobamate, meprobamate started appearing in the urine within 30 
minutes and by 24 hours most of it was excreted from the body (Walkeinstein et al 1958). 
Protein binding of meprobamate is negligibly small (14%–24%) and the volume of distribution 
(Vd) was reported to be 0.70 L/kg and is not significantly altered in overdose (Verpooten et 
al., 1982). 50% of amount of drug is unchanged meprobamate. Meprobamate is primarily 
metabolized to inactive metabolites by the liver, primary metabolite being hydroxyl-
meprobamate and 10%–20% of the parent compound is excreted by the kidneys (Bismuth et 
al., 1985). Elimination can be described by first-order pharmacokinetics and reported 
elimination half-lives range between 6.4 hours and 16.6 hours in therapeutic dose and were 
similar in overdose (Hollister et al., 1964; Maddock et al., 1967). 
Meprobamate Side effects, Abuse and Withdrawal 
             Meprobamate was the first block-buster drug, selling billions of pills. It was supposed 
to be free of toxic side effects, abuse and dependence potential. A common side effect of 
meprobamate associated with regular use is allergic skin rashes, which appear in the form of 
urticaria or erythema. They have been found in as high as 1-2% of patients taking the drug 
(Hollister, 1957). Allergic rashes respond to drug withdrawal or concomitant use of anti-
histaminic medication. More severe form of skin reactions, like pustular skin lesions and 
purpura, have also been reported (Friedman et al., 1956; Holoubek et al., 1957). These 
promptly respond to discontinuation of the drug and corticosteroid therapy (Stroud, 1957). 
Other common side effects associated with meprobamate use include nausea, dizziness, 
drowsiness and fainting spells especially found when initial dose is more than 400 mg. An 




upon withdrawal (Pennington, 1957). A case of death with aplastic anemia has also been 
reported with meprobamate use (Meyer et al., 1957).  
             Meprobamate was initially advertised as a non-addictive drug. Its good tranquilizing 
effect along with relatively good safety profile prompted it to be sold without a prescription. 
But many cases characteristic of a typical habit-forming drug were reported in the initial few 
years of use of the drug.  Addiction or a habit formation to a drug, has the following 
characteristics:  (1) an intense craving for the drug based on its euphoric effects, (2) tolerance 
build up, requiring increasingly larger doses to produce the same effect, and (3) withdrawal 
symptoms associated with sudden discontinuation of the drug (Lemere, 1956). An example 
include a patient with a history of alcohol and barbiturate abuse and suffering excessive anxiety 
at work, was prescribed meprobamate 400 mg 3 times a day. He had a good response, but had 
to consume increasing doses of the drug to sustain the same response. Sometimes it was 50-70 
tablets a day. An attempt at quitting led to anxiety and tremor and a grand mal seizure after 20 
hours. Upon admission he was stuporous, confused and anxious and suffered another grand 
mal seizure. He recovered after gradual weaning of the drug (Mohr et al., 1958). In another 
studiy, patients did not show dependence (physical or psychic) or  withdrawal even after 
prolonged use of clinically effective dose (Boyd et al., 1958). So, other factors have been 
associated with the development of meprobamate addiction and dependence, which include 
amount of drug intake, previous history of drug abuse and personality of the patient. At the 
peak of its use, meprobamate had been implicated in 7% of self-poisoning cases (Allen et al., 
1977). 
             Commonly known side effects of a meprobamate overdose include central nervous 
system (CNS) depression, weakness, clonus and hyperactive reflexes, tachycardia, 




symptoms (Bramness et al., 2005) . Meprobamate intoxication is often serious and sometimes 
fatal (5%), resulting from hemodynamic disturbance and circulatory collapse, secondary to 
severe acute cardiac failure (Charron et al., 2005).  In a case report, Lhoste et al., 1977, 
suggested a predominant cardiogenic mechanism responsible for such hemodynamic failure. 
The mechanism of cardiac toxicity is unknown.  Patients with meprobamate poisoning were 
shown to have a low cardiogenic index, ejection fraction, high right atrial pressure and 
pulmonary capillary wedge pressure, showing a cardiogenic shock and thus a direct cardiac 
effect (Lhoste et al., 1977; Charron et al., 2005). In a case of fatal meprobamate poisoning, 
maximum meprobamate accumulation was found in heart, showing a possible direct cardio 
toxic effect (Kintz et al., 1988). Also, ionotropic drugs have been useful in such cases, showing 
presence of a cardiac depression (Lhoste et al., 1977; Taboulet et al., 1994).  A related 
compound, felbamate, is protective in cerebral ischemia and hypoxia (Wallis et al., 1992) via 
a vasodilatory mechanism. Meprobamate, having a similar structure, may share some of this 
vasodilatory effect. In the case report of Lhoste et al. 1977, a patient with severe meprobamate 
poisoning had decreased peripheral resistance, unlikely in an isolated cardiogenic shock.  Thus, 
meprobamate-mediated hypotension is due to dual mechanism of direct cardiac depression and 
peripheral vasodilatory effect. 
             An overdose of meprobamate also leads to an altered consciousness which corresponds 
to its plasma concentrations. Below 5 mg/100 ml, patients have been found to be awake. A 
non-serious coma occurs between 6-12 mg/100 ml and a deep coma is induced at 
concentrations greater than  10 mg/100 ml (Maddock et al., 1967).  
             Recently, acute pancreatitis has also been reported as a possible effect of meprobamate 
poisoning (Fathallah et al., 2011). Possible mechanism is stasis due to hypovolemia leading to 




              
 
GABAA receptor 
             GABA is the primary inhibitory neurotransmitter in the CNS (Bormann, 2000) with 
glycine, being the primary inhibitory neurotransmitter in the spinal cord (Betz et al., 1988; 
Moss et al., 2001). Primary excitatory neurotransmitter in the CNS is the glutamate (Meldrum, 
2000). GABA is synthesized from glutamate in a one step process by enzyme, L-glutamic acid 
decarboxylase (GAD). Thus along with itself working as a neurotransmitter and a co-factor for 
folic acid and hormone TSH (Thyrotropin releasing hormone), glutamate is used for the 
synthesis of GABA (Erlander et al., 1991)(figure 1). 
             GABA receptors are of 3 types: GABAA, GABAB and GABAC. Considering similar 
functional nature of GABAC receptor as GABAA, they have been nominated as a part of 
GABAA receptor (Barnard et al., 1998). But there has been an accumulating evidence of a 
distinct structure, function, pharmacology and genetics which makes the case of a separate 
nomenclature (Bormann, 2000). 
             GABA interacts with GABAA receptors resulting in an opening of chloride channel 
leading to depolarization and inhibitory post synaptic potential (IPSP). In some cases GABA 
can be excitatory in nature. Example, in developing neurons, with high intracellular chloride 
concentrations, a GABA interaction leads to an outward chloride flow and generation of an 
excitatory post synaptic potential (EPSP) (Rivera et al., 1999). This phenomenon has a 
profound effect on survival and differentiation during neuronal development (Ben-Ari et al., 









































































             
 
              GABAA receptors are members of cys-loop ligand-gated ion channels. Cys-loop is a 
characteristic loop formed by a disulfide bond between two cysteine (Cys) residues which are 
13 highly conserved amino acids apart near the N-terminal extracellular domain of the alpha 
subunit. Common members of this group are nicotinic acetylcholine receptors, Zn++ receptors, 
type 3 serotonin (5HT3) receptors, glycine and GABAC receptors (Schofield et al., 1987; 
Connolly et al., 2004). GABAA receptors are sensitive to bicuculline (Bormann, 1988; 
Bormann, 2000) GABAA receptors are sites for many ligands like benzodiazepines, 
barbiturates, alcohol, anesthetics and muscle relaxants like carisoprodol and meprobamate 
(Akaike et al., 1985; Orser et al., 1994; Sigel et al., 1997; Kumar et al., 2015). GABAB 
receptors are metabotropic G protein-coupled receptors sensitive to baclofen (Bormann, 1988; 
Bowery, 1989; Marshall et al., 1999). They mediate their effect via signal transduction 
pathways (Couve et al., 2000).  Located on the presynaptic membrane, they inhibit the release 
of inhibitory GABA in synaptic terminal. So overall having an excitatory effect. GABAB as a 
therapeutic target has been less exploited (Bowery, 1989; Marshall et al., 1999). A different 
type of receptor not sensitive to bicuculline or baclofen, previously known as GABAC receptors 
(Johnston, 1996), are sensitive to GABA and the  GABA analogue, aminocaproic acid. They 
are also ligand-gated ion channel, composed of ρ-subunits, with the opening of chloride 
channel on activation by GABA (Bormann et al., 1995; Johnston, 1996). However, they are 
more sensitive and have a very weak desensitization. GABAC receptors are normally located 
in the bipolar cells of retina (Shimada et al., 1992). As stated earlier, GABAC has unique 
pharmacology compared to GABAA receptor. It is insensitive to bicuculline and baclofen 




GABAA, while the ρ2-homomeric or ρ1ρ2 were not inhibited by picrotoxin (Cutting et al., 
1991; Enz et al., 1998; Feigenspan et al., 1998; Enz et al., 1999). 
 
Structure of GABAA receptor and subunits classes and roles 
             GABAA receptor is a member of cys-loop ligand gated ion channels. Much has been 
learned about the structure of of pentameric LGICs by solving of crystal structure of 
acetylcholine binding protein (AchBP) (Brejc et al., 2001). Recently structure of GABAA 
receptor itself has been solved (Miller et al., 2014). Cys loop ligand-gated ion channels are 
pentameric in nature, i.e., each ion channel consists of 5 subunits (Toyoshima et al., 1990; 
Nayeem et al., 1994). Each subunit consists of long extracellular N terminal domain, a short 
extracellular c terminal domain, four trans-membrane (TM1-TM4) domains and connecting 
loops. Connecting loops are short intracellular TM1-TM2 and a long intracellular TM3-TM4. 
There is also a short extra-cellular TM2-TM3 connecting loop (Schofield et al., 1987; Unwin, 
1993). Five of these subunits come together to form pentameric ion channel. The TM2 domain 
of all the five subunit form the pore of the channel (Unwin, 1993; Xu et al., 1996). Extracellular 
TM2-TM3 play an important part in channel gating, i.e., carrying information after binding of 
ligand, leading to channel opening (Miyazawa et al., 2003; Thompson et al., 2010).  
             Above receptors were isolated using benzodiazepine affinity chromatography leading 
to partial sequencing and cloning of two receptor genes. cDNAs for the two polypeptides 
formed receptors with GABA activated current in Xenopus oocytes and these were designated 
as α and β (Mohler et al., 1980; Schoch et al., 1985; Schofield et al., 1987; Sieghart, 1995). 
             These were used as probes to identify other subunits. Those with maximum homology 




assigned different Greek letter. Thus so far the following GABAA receptor subunits have been 
identified. α1-6, β1-3, γ1-3, δ, , ,  and ρ1-3 (Lynch et al., 1995; Lynch et al., 1997; Siegwart 
et al., 2002). Some splice variants have also been identified. For example, the γ2 has a short 
and a long form differing in the 8 amino acid insert in the intracellular (Whiting et al., 1990). 
Similarly a short and a long form splice variant have also been identified for β2-subunit 
(McKinley et al., 1995) .  
             So the above subunits assemble together to form hetero-pentameric, chloride 
permeable channel. Out of the many possibilities of combinations, most common GABAA 
receptor expressed in brain is 2 α, 2 β and one γ stoichiometry with the γ subunit, being able to 
be replaced by δ, ,  or  subunit (Im et al., 1995; Chang et al., 1996; Tretter et al., 1997; 
Baumann et al., 2001; Olsen et al., 2008). Out of all possible combinations, α1β2γ2 is most 
abundant with approximately 60 % of the total GABAA receptor population. Distribution of 
other combinations are α2β3γ2, 15-20%; α3βnγ2, 10-15%; α4βnγ2 or α4βnδ, 5%; α5β2γ2, < 
5%; α6β2/3γ2, < 5% (Fritschy et al., 1995). Some GABAA receptor have two different α-
subunits. In recombinant receptors, the α-subunit adjacent to the γ2-subunit determines the 
sensitivity to the BZDs (Benke et al., 2004). Binding of GABA occurs at the interface of the α 
and β-subunits (Baumann et al., 2003) while benzodiazepines bind at the interface of α and γ-
subunits (Sigel et al., 1997), leading to influx of chloride ions and generation of IPSP. 
             Functional roles of various subunits have been assessed using histidine to arginine 
point mutations at a conserved residue. In α1, α2, α3 or α5 subunit, this mutation abolish the 
binding of diazepam, whereas action of GABA is preserved (Rudolph et al., 1999; McKernan 
et al., 2000; Crestani et al., 2002; van Rijnsoever et al., 2004). The positions are, α1H101R, 




             From the above mutation, it was assessed that α1 subunit-containing GABAA 
receptors mediate sedative, partly anti-convulsant and anterograde amnestic action (Rudolph 
et al., 1999); α2 subunit containing GABAA receptors mediate anxiolytic and myorelaxant 
actions (large portion of it) (Low et al., 2000; Crestani et al., 2001); rest of myorelaxant action 
is mediated by α3 and α5 subunit containing GABAA receptors (Low et al., 2000; Crestani et 
al., 2001; Crestani et al., 2002); α5-containing GABAA receptor further mediate tolerance to 
sedative action (van Rijnsoever et al., 2004); and addictive property α1-containing GABAA 
receptors (Tan et al., 2010).  
             β-subunit also has important implications in health and disease. β3 subunit has been 
associated with schizophrenia (Huang et al., 2014), genetic epilepsies (Macdonald et al., 2010), 
autism (Delahanty et al., 2011), cleft palate (Inoue et al., 2008) as well as substance abuse 
(Chen et al., 2014). Angelman syndrome, associated with mental disorders and developmental 
delay and gait ataxia, is associated with the deletion of GABAA receptor β3 subunit (Williams 
et al., 1995; DeLorey et al., 1998). In PTSD, a heterogenicty of β3 GABAA receptor is 
associated with higher degree of anxiety insomnia and social dysfunction than a homozygocity 
(Feusner et al., 2001).  
Various modes of GABAA receptor activation 
             GABAA receptor synaptic communication transmits a pre-synaptic signal. 
Depolarization following an action potential, lead to a calcium influx. Calcium causes synaptic 
vesicles to fuse with the presynaptic membrane. Each vesicle release thousands of GABA 
molecules, leading to a concentration in milli-molar range in the synaptic cleft. Some post-
synaptic receptors exposed to GABA, have synchronous activation, leading to a phasic current 




GABAA receptors that mediate phasic currents are made up of mostly α1-3, β and γ subunits 
(Rudolph et al., 2004). Phasic currents are characterized by fast activation, fast desensitization 
and fast deactivation. One the other hand there is a tonic current mediated by highly sensitive 
extrasynaptic-GABAA receptors, characterized by slow desensitization which can also open 
spontaneously in absence of GABA (Brown et al., 2002; Tang et al., 2010; Wlodarczyk et al., 
2013). Extrasynaptic GABAA receptors are δ-containing (with mostly α1, α4 or α6) or γ subunit 
with α5 (Fritschy et al., 1998; Brunig et al., 2002). δ subunit expressing receptors are 
characterized by many remarkable properties. As stated earlier, they generate a tonic current 
which are important component of CNS inhibition (Maguire et al., 2009; Bonin et al., 2011; 
Sarkar et al., 2011). They regulate behaviors like memory and anxiety (Whissell et al., 2013; 
Cushman et al., 2014; Lee et al., 2014; Paydar et al., 2014). They have a remarkable property 
of different expression levels under different physiological and pathological conditions. 
Neurosteroids mediate a stress-induced increase in expression of α4βδ GABAA receptors 
(Maguire et al., 2005; Shen et al., 2005). Since these receptors constrain memory, their 
upregulation in hippocampus may lead to stress-induced memory impairment. During 
pregnancy, stimulation by steroid hormones cause upregulation of δ subunit (Smith et al., 2006; 
Maguire et al., 2008). A partial or complete rebound following pregnancy may be responsible 
for post-partum depression and abnormal maternal behavior which responds to 
pharmacologically increasing delta activity. Expression of δ subunit and α4 subunit is reduced 
in pre-frontal cortex (of suicide victims) in depression (Merali et al., 2004). δ-Expression is 
reduced in schizophrenia (Hashimoto et al., 2008b; Hashimoto et al., 2008a; Maldonado-
Aviles et al., 2009) and an upregulation is observed in cases of stroke and traumatic brain 
injury (Clarkson et al., 2010; Mtchedlishvili et al., 2010; Kharlamov et al., 2011). An 
expression of δ subunit in various brain regions and its functional role is stated in figure 4. So 










Figure 3: Representation of GABAA receptors. A, GABAA receptor subunit consists of 
long N-terminal domain, short C-terminal domain, 4 transmembrane (TM1-TM4) domain and 
long intracellular TM3-TM4 loop. B, 5 of the subunits assemble to form a pentameric cys loop 
ligand gated ion channel with GABA binding site between α and β-subunit and benzodiazepine 
binding site between α and γ-subunit. Note, in recombinant receptors, the α-subunit adjacent 
to the γ-subunit determine the sensitivity to the benzodiazepines. C, synaptic and extra-
synaptic GABAA receptors composed of α1-3, β , γ and α4-α6, β, δ respectively. α 5 βγ also 


























Figure 4: Delta GABAA expression and function in CNS. Red show a high expression level 



































Pharmacology of GABAA receptors 
             Ligands have various modes of action on GABAA receptors. These include direct 
activation, allosteric modulation, inverse agonism and antagonism.  Direct activation involves 
activation of receptor in the absence of GABA via the GABA site or a different site. Common 
ligands capable of direct activation are barbiturates, common tranqilizers and muscle relaxants 
like carisoprodol (Kumar et al., 2015)  and meprobamate (Kumar et al. 2015, accepted pending 
revision).  Ligands capable of direct activation at all the α subunits are commonly associated 
with fatal complications (Rho et al., 1997; Fass, 2010). Allosteric modulation is effect of a 
ligand on GABA mediated current via a different binding site. Common ligands capable of 
allosteric modulation are benzodiazepines and barbiturates (Hunkeler et al., 1981). 
Barbiturates, carisoprodol and meprobamate are capable of both direct action and allosteric 
modulation whereas benzodiazepines do not have a direct gating effect at GABAA receptors. 
An inverse agonist is a ligand having an effect opposite to that of an agonist (Braestrup et al., 
1982; Bonetti et al., 1988). Antagonists do not have effects on their own on the receptor but 
block current by both the agonists and the inverse agonists. Common antagonists at GABAA 
receptors are picrotoxin and bicuculline (Bormann, 2000). Common antagonist at the 









Aims of the study 
             So, the main aim of this study is to understand a detailed mechanism of action of 
meprobamate on the various subunits of GABAA receptors. To understand whether 
meprobamate has a direct gating, allosteric modulatory or inhibitory effects on GABAA 
receptors. Meprobamate, though earlier was widely prescribed and later controlled, is the major 
metabolite of currently widely prescribed muscle relaxant, carisoprodol. Carisoprodol has 
direct gating, allosteric modulatory and inhibitory actions on GABAA receptor subunits. We 
wanted to test the hypothesis that meprobamate also has similar actions on GABAA receptors 
and the difference attributed to the difference in the structure of the two ligands. Carisoprodol 
has an isopropyl group that is absent in meprobamate. 
             Mechanism of action of meprobamate, known so far, is its action on GABAA receptor 
in a barbiturate like manner. So, we also wanted to test how similar and different is the action 
of meprobamate to barbiturates, represented in our studies by pentobarbital. 
             We further set out to explore the specific amino acids and domains responsible for the 
various modes of action of meprobamate on GABAA receptors. To summarize, the aims of 
study are as follows: 
 AIM 1: To determine the degree to which the lack of the isopropyl group may alter 
potency, efficacy and subunit preferring effect of meprobamate compared to CSP 
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Meprobamate is a schedule IV anxiolytic and the primary metabolite of the muscle relaxant 
carisoprodol.  Meprobamate modulates GABAA (-aminobutyric acid type A) receptors, and has 
barbiturate-like activity.  To gain insight into its actions, we have conducted a series of studies 
using recombinant GABAA receptors. In xz GABAA receptors (where x = 1-6 and z = 1-3), 
the ability to enhance GABA-mediated current was evident for all  subunit isoforms, with the 
largest effect observed in 5-expressing receptors. Direct gating was present with all  subunits, 
although attenuated in α3-expressing receptors.  Allosteric and direct effects were comparable in 
112 and 122 receptors, whereas allosteric effects were enhanced in 12 compared to 
122 receptors. In “extrasynaptic” (α1β3δ and α4β3δ) receptors, meprobamate enhanced EC20 
and saturating GABA currents, and directly activated these receptors.  The barbiturate antagonist 
bemegride attenuated direct effects of meprobamate.  Whereas pentobarbital directly gated 
homomeric β3 receptors, meprobamate did not, and instead blocked the spontaneously open current 
present in these receptors. In wild type homomeric ρ1 receptors, pentobarbital and meprobamate 
were ineffective in direct gating; a mutation known to confer sensitivity to pentobarbital did not 
confer sensitivity to meprobamate.  Our results provide insight into the actions of meprobamate 
and parent therapeutic agents such as carisoprodol.  Whereas, in general, actions of meprobamate 
were comparable to those of carisoprodol, differential effects of meprobamate at some receptor 
subtypes suggest potential advantages of meprobamate may be exploited.  A re-assessment of 
previously synthesized meprobamate-related carbamate molecules for myorelaxant and other 
therapeutic indications is warranted. 
 




1.  Introduction 
 Meprobamate, a propanediol carbamate, was the first drug to be used as an anxiolytic agent, 
and was also prescribed as an anticonvulsant and sedative/hypnotic (Hendley et al., 1954). By the 
late 1950s, meprobamate was the most widely prescribed drug in the United States and in many 
other countries. It retained this position until diazepam the benzodiazepine diazepam was 
introduced into clinical use in late 1960 (Berger, 1964; Greenblatt et al., 1974). Within two years 
of introduction of meprobamate, cases of its abuse and withdrawal after long term use were reported 
(Ewing et al., 1957), and it was relatively soon thereafter listed as a controlled substance.   
While meprobamate itself is no longer widely used, drugs metabolized to meprobamate are 
widely available, and misuse of these drugs is associated with serious side effects.  One such drug 
is the centrally acting skeletal muscle relaxant carisoprodol, which remains highly prescribed for 
low back pain (Toth et al., 2004; Sullivan, 2015).  Use of carisoprodol is associated with abuse and 
dependence, and related dangers such as psychomotor impairment (Elder, 1991; Rust et al., 1993; 
Zacny et al., 2011, 2012). Dependence and severe withdrawal may lead to seizures and death 
(Adams et al., 1975; Elder, 1991; Littrell et al., 1993; Rust et al., 1993; Reeves et al., 2003; Zacny 
et al., 2011; Zacny et al., 2012). Although carisoprodol has its own independent effects (Gonzalez 
et al., 2009b), many of its therapeutic and abuse-dependent effects are likely due to its metabolite 
meprobamate, which differs from carisoprodol by the absence of an isopropyl group (Fig. 1).  
Indeed, the half-life of meprobamate far exceeds that of carisoprodol ( t ½  for carisoprodol of 1-2 
hours (Olsen et al., 1994) and t ½ for meprobamate between 6.4 hours and 16.6 hours (Hollister et 
al., 1964; Maddock et al., 1967).     
Meprobamate has been shown to have barbiturate-like activity at neuronal GABAA 
receptors (Rho et al., 1997), the predominant inhibitory neurotransmitter receptor in the central 
nervous system and the target of many therapeutics. Carisoprodol has similarly been suggested to 
have barbiturate-like actions (Gonzalez et al., 2009a).  A detailed understanding of meprobamate’s 




interaction with GABAA receptors may be subunit-dependent is unknown. As the extensive array 
of GABAA receptor configurations that exist throughout the CNS contribute to specific 
physiological and pharmacological responses of GABA and modulatory agents (Olsen et al., 2008), 
an understanding of meprobamate’s subunit-dependent actions could prove enlightening regarding 
therapeutic and adverse effects of both it and parent therapeutics that are metabolized to 
meprobamate, such as carisoprodol.  We have thus assessed the potential subunit-dependent 
interaction of meprobamate at these receptors and have further explored potential commonality and 








2. Materials and Methods 
 
2.1 Cell Culture and Transfection  
Human embryonic kidney 293 (HEK293) cells, stably or transiently expressing varying 
GABAA receptor subunits, were used in the present study.  For transient expression, cells were 
transfected with human GABAA α1-α6; human β1-2; and human 2s (short isoform) cDNA in a 
1:1:5 ratio (2 g total cDNA) using PolyJetTM in vitro transfection reagent (SignaGen Laboratories, 
Jamesville, MD). The 2s subunit will be referred to as 2 from here forward.  For studies assessing 
meprobamate effects in a model of extrasynaptic receptors (rat 13 and 43 subunits), a total 
of 3 g of cDNA in a transfection ratio of 2:1:0.25 for α:β:δ plasmids was used (Wagoner et al., 
2010). For studies on wild type 3 homomeric receptors, wild type 1 subunits, and barbiturate-
sensitive 1 (W328M) subunits (generated previously in our lab, Gonzalez et al, 2009b), 2 g of 
cDNA was transfected. The rat GABAA α4 subunit cDNA was purchased from Genescript 
(Piscataway, New Jersey).  Human GABAA α1 subunit cDNA was generously provided by Neil 
Harrison (Columbia University Medical Center, New York). The wild-type human GABA 1 
subunit was generously provided by David Weiss (University of Texas Health Science Center at 
San Antonio).  HEK293 cells stably expressing human 222 receptors were also used. A 
complete description of the preparation and maintenance of these stable cell lines has been 
published previously (Hawkinson et al., 1996).  Cells were plated on glass coverslips coated with 
poly-L-lysine in 35-mm culture dishes, and maintained at 37C in a humidified incubator with an 
atmosphere of 5% CO2.  In all cases, cells were used for recording 24-72 hr after transfection.  
 
2.2 Electrophysiology  
Whole-cell patch clamp electrophysiology was used to assess GABA-, meprobamate–, or 




temperature (22 - 25 C) with the membrane potential clamped at -60 mV. Patch pipettes of 
borosilicate glass (1B150F; World Precision Instruments, Inc., Sarasota, FL) were pulled 
(Flaming/Brown, P-87/PC; Sutter Instrument Company, Novato, CA) to a tip resistance of 4–6MΩ. 
Patch pipettes were filled with a solution consisting of 140 mM CsCl, 10 mM EGTA-Na+, 10 mM 
HEPES-Na+, and 4 mM Mg2+-ATP, pH 7.2. Coverslips containing cultured cells were placed in the 
recording chamber on the stage of an inverted light microscope and superfused continuously with 
an external solution consisting of 125 mM NaCl, 20 mM HEPES, 3 mM CaCl2, 5.5 mM KCl, 0.8 
mM MgCl2, and 10 mM glucose, pH 7.3. Agonist-induced Cl- currents were obtained with an 
Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) equipped with a CV-203BU 
headstage. Currents were low-pass filtered at 5 kHz, monitored simultaneously on an oscilloscope 
and a chart recorder (Gould TA240; Gould Instrument Systems Inc., Cleveland, OH), and stored 
on a computer using an on-line data acquisition system (pCLAMP 6.0; Axon Instruments) for 
subsequent off-line analysis. 
 
2.3 Chemicals and solutions 
 Meprobamate, carisoprodol, pentobarbital, diazepam, THIP (4,5,6,7-
tetrahydroisoxazolo(5,4-c)pyridin-3-ol), salts and buffers were purchased from Sigma Aldrich (St. 
Louis, MO). GABA was obtained from Acros Organics (New Jersey, US). Bemegride was obtained 
from Pfaltz & Bauer, Inc. (Waterbury, CT). Stock solutions of meprobamate, pentobarbital and 
carisoprodol were made using dimethylsulfoxide (DMSO).  Drugs were diluted in normal saline, 
so that the final DMSO concentration (vol/vol) of the test solutions was ≤0.3%.  GABA, diazepam 
and bemegride stock solutions were prepared using de-ionized H2O.  All stock solutions were stored 
at -20 C. On experimental days, drug-containing solutions were prepared from stock by serial 





2.4 Experimental Protocol  
GABA (with or without modulatory ligand), meprobamate, carisoprodol or pentobarbital 
were prepared in external solution on the day of use and applied via a 16-barrel rapid perfusion 
system  in which all barrels (200 µm outer diameter quartz tubes; ALA Scientific, Folsom, CA) 
emptied via a common tip positioned adjacent to the cell under study.  Flow through each barrel 
was pressure fed and regulated by solenoid or pinch valves operated by a programmable 
microprocessor-based controller. Only one valve was open at a time, and the buffer solution was 
applied continuously between drug applications via gravity or positive pressure. As per the 
manufacturer specifications, solution flow rate as configured in the present studies is approximately 
3 l/second, and exchange rate is approximately 5 msec. For some experiments, ligands were 
applied via gravity flow using a Y-tube placed adjacent to the cell.  
The modulatory effects of meprobamate on GABA-gated currents were assessed using an 
EC20 gating concentration of GABA as the control. This gating concentration was selected to ensure 
there was a sufficient range to observe the full allosteric potential of meprobamate. To ensure the 
gating concentration was approximately an EC20, control responses were compared to the maximal 
GABA-gated current for each individual cell. On a cell by cell basis, control GABA currents were 
deemed acceptable for assessment of allosteric modulatory effects of meprobamate if they were 
within a 15-25 % range of maximal current for that particular cell.  Control responses were 
established by observing two consecutive agonist-activated currents that varied in amplitude by no 
more than ± 10%. In our analyses of the modulatory effects of meprobamate, peak current 
amplitude was defined as the maximum current elicited by meprobamate.  For studies investigating 
meprobamate-mediated currents, meprobamate was dissolved in external solution and applied in 
the manner described above.  In all studies assessing direct gating effects of meprobamate, the 
magnitude of the response was expressed relative to the maximal effect of GABA (designated 
100%).  In studies on β3 homomeric receptors, the magnitude of meprobamate-mediated block of 




(designated 100%).  For configurations, GABA-gated control currents were recorded in the 
presence of diazepam to confirm incorporation of the 2 subunit. Presence of the δ subunit in α1β3δ 
and α4β3δ receptors was confirmed by loss of inhibition to 1 µM Zn2+. 
 
 
2.5 Data Analysis  
             To ensure equipotent concentrations were used for gating, GABA concentration-response 
data were collected for all synaptic and extrasynaptic GABAA receptors tested, (Table 1). From 
these data, EC20 and saturating GABA concentrations were calculated for each configuration and 
used in subsequent investigations of the allosteric and direct effects of meprobamate, respectively.  
For studies assessing allosteric actions of meprobamate, a correction was applied to subtract 
underlying direct gating effects, which were present at higher meprobamate concentrations.  All 
data are presented as mean ± S.E.M. For experiments in which three or more datasets were 
statistically analyzed, one-way analysis of variance was conducted, followed by a Tukey-Kramer 
post hoc test as indicated.  For those experiments in which two datasets were analyzed, Student’s 
t-tests (paired or unpaired) were conducted.  In all cases, statistical significance was designated at 









3.1 α subunit isoform influence on direct and allosteric actions of meprobamate 
 Direct effects of meprobamate were assessed in x22 GABAA receptors, where x = α 
subunit 1-6.  We initiated direct gating studies using concentrations of meprobamate as low as 100 
M; as direct gating effects were not generally observed below 1 mM, we report here direct gating 
effects of 1, 3 and 10 mM meprobamate. Meprobamate directly gated each of the configurations 
tested at high concentrations, evoking inward currents in the absence of GABA (Fig. 2). The 
relatively low apparent affinity of meprobamate combined with limits on its solubility precluded 
definitive calculation of maximal meprobamate-gated current. At 10 mM, meprobamate-gated 
current was of similar magnitude in α1-, α2-, α4-, α5- and α6β2γ2s GABAA receptors (20-36% of 
maximal GABA current), and significantly less (7%) in α3-expressing receptors (Fig. 2).  
We also assessed  subunit isoform effects on allosteric modulatory actions of 
meprobamate.  Meprobamate positively modulated the effects of GABA EC20 concentration in all 
configurations tested (Fig. 3).  3 mM meprobamate on average roughly doubled the amplitude of 
the GABA EC20 current for most subunit isoforms.  We observed a somewhat enhanced effect in 
receptors expressing the 5 subunit, as 3 mM meprobamate elicited a potentiating effect of more 
than 3-fold (Fig. 3).  
 
3.2  subunit isoform influence on direct and allosteric actions of meprobamate 
To assess whether the  subunit isoform affected the actions of meprobamate, we assessed 
both direct and allosteric effects of it in α1β2γ2 and α1β1γ2 receptors.  We observed no significant 
difference in the magnitude of current elicited by meprobamate alone in these receptors, as 10 mM 
meprobamate elicited currents roughly 1/3 the amplitude of peak GABA current in both α1β2γ2 




With regard to  subunit effects on allosteric actions of meprobamate, we found receptors 
expressing either β1 or β2 subunits (in combination with α1 and 2) showed similar allosteric 
modulation by meprobamate.  In both receptors, 3 mM meprobamate effectively doubled the 
amplitude of GABA-gated current (Fig. 3C).   
 
3.3  subunit isoform influence on direct and allosteric actions of meprobamate 
Presence of a  subunit is critical for the allosteric actions of benzodiazepines  (Pritchett et 
al., 1989), but not for direct or allosteric effects of other ligands such as barbiturates (Horne et al., 
1993) or neurosteroids (Hosie et al., 2006).  To assess the extent to which the  subunit impacts 
actions of meprobamate, we tested effects of it in receptors lacking the 2 subunit.  In comparison 
to α1β2γ2 receptor, direct gating in α1β2 receptor was generally comparable.  There was a 
statistically smaller direct gating response at 1 mM meprobamate in α1β2 receptor compared to 
α1β2γ2 receptor, but this difference was modest and not present at other concentrations tested (Fig. 
2D).   
The 2 subunit had a more prominent effect on allosteric modulation by meprobamate.  Its 
presence significantly attenuated the ability of meprobamate to allosterically an EC20 concentration 
of GABA at all concentrations of MEP above 100 M.  At 1 and 3 mM MEP, the magnitude of 
enhancement in α1β2 receptors was more than twice that observed in α1β2γ2 receptors (Fig 3D).    
 
3.4 Effects of meprobamate on -subunit containing “extrasynaptic” receptors 
GABA and ligands that regulate its receptors may act at synaptic or extrasynaptic sites.  To 
assess the influence of meprobamate extrasynaptically, we studied its effect in recombinant α4β3 
and α1β3receptors, models of extrasynaptic GABAA receptors.  As reported by others (Brown et 
al., 2002), sensitivity of α4β3 receptors to GABA was high, with an EC50 of 0.04 ± 0.02 µM.  As 




that of GABA itself.  This direct gating effect was concentration-dependent, and saturated at 3 mM 
meprobamate.  We found very similar effects for the ability of meprobamate to directly gate 
α1β3receptors.  Sensitivity to the direct gating effects in extrasynaptic receptors was comparable 
to that observed in synaptic receptors. Current gated by meprobamate rapidly decayed following 
activation, and we noted a prominent rebound effect following termination of ligand application 
(Fig 4A, arrow).  GABA is not a full agonist in expressing receptors (Brown et al., 2002); we 
observed the same effect, as the agonist THIP elicited a current 151 ± 12% of that elicited by 
saturating GABA.  
             We also assessed the extent to which meprobamate might allosterically potentiate 
extrasynaptic GABAA receptors.   As illustrated in Fig.  5, meprobamate enhanced GABA-gated 
(EC20) current, with a threshold effect at 100 M, and a maximal effect observed at 1 mM.  The 
sensitivity and magnitude of the potentiating effect is comparable to that observed in synaptic 
receptors.    
  Pentobarbital and carisoprodol, the parent molecule to meprobamate, have been reported 
to enhance maximal GABA-gated current in δ-subunit containing receptor (Feng et al., 2004; 
Kumar et al., 2015). We thus assessed for this capability with meprobamate.  Co-application of 1 
mM  meprobamate with 1 mM GABA (EC95+) to α4β3 receptors resulted in a current 183 ± 17% 
of that seen with maximal GABA alone.   As anticipated, 100 µM pentobarbital, which was used 
as a positive control, showed enhancement of maximal GABA-gated current (to 223 ± 38% of 
maximal GABA, Fig. 6B). No enhancement was observed in α1β3γ or α1β3 subunit containing 
receptors with meprobamate or pentobarbital (Fig. 6B).       
 
3.5 Further assessment of the barbiturate-like effects of meprobamate 
Based on a mechanistic assessment of its effects in GABAA receptors recorded from 




activity (Rho et al., 1997). Our results are broadly consistent with that suggestion.  We thus 
conducted additional studies to test further commonality of action between meprobamate and 
pentobarbital.   
Bemegride is known to antagonize pentobarbital stimulus effect in animal models 
(Schechter, 1984) and phenobarbital direct gating effects in mouse spinal neurons (Mistry et al., 
1990). We thus assessed the influence of bemegride on the direct gating effects of meprobamate.   
As shown in Figure 7, meprobamate-mediated direct gating current was significantly and reversibly 
attenuated by bemegride.  The ability of bemegride to antagonize meprobamate-activate current 
was greater when tested against a lower concentration of meprobamate, demonstrating a 
concentration-dependent effect.  
  1 homomeric GABA receptors are anion-selective cys loop ligand-gated channels, with 
a pharmacology distinct from that of heteromeric GABAA receptors (Amin et al., 1994). They are 
found in very high concentration in retina and other visual areas (Enz et al., 1995; Boue-Grabot et 
al., 1998). Barbiturates cannot directly activate wild type 1 homomeric GABA receptors, but can 
when tryptophan at position 328 is mutated to methionine (W328M) (Amin, 1999). We assessed 
whether meprobamate can gate wild type or W328M 1 homomeric GABA receptors. In wild type 
homomeric ρ1 receptors, both pentobarbital and meprobamate were ineffective in direct gating 
(Fig. 7A, 7B). As originally reported (Amin, 1999), we observed that the W328M mutation in the 
1 subunit conferred sensitivity to direct gating effects of pentobarbital. In contrast, the W328M 
mutation did not confer on meprobamate the ability to directly gate the channel (Fig. 7A, 7B).  
Homomeric β3 receptors do not appear to form natively, but they can form a functional 
receptor in vitro, and thus are a useful tool for studying drug action (Davies et al., 1997; Chen et 
al., 2012). Homomeric β3 receptors are spontaneously open, and they can be directly activated by 
barbiturates (Davies et al., 1997).  We evaluated whether meprobamate had direct gating effects in 




receptors. Instead, meprobamate, blocked the spontaneously open current present in homomeric β3 
receptors (Fig. 7A, 7B). This effect was concentration-dependent, and approached the efficacy of 




4.  Discussion 
                This is the first study to assess subunit-dependent effects of meprobamate at its major 
target, GABAA receptors.  Drugs metabolized to meprobamate, such as carisoprodol, have 
remained widely utilized.  Carisoprodol was actually synthesized as an alternative to meprobamate, 
and early studies suggested it had a profile that was preferable to meprobamate (Berger et al., 1960). 
Early metabolism studies in dogs indicated the primary metabolite of carisoprodol was hydroxyl-
carisoprodol (Douglas et al., 1962).  Toxicology studies some years later demonstrated that in 
humans, carisoprodol was in fact metabolized primarily to meprobamate, which has a half-life that 
is several-fold longer than that of carisoprodol (Bramness et al., 2004; Olsen et al., 1994).  Whereas 
the recent scheduling of carisoprodol will likely result in a reduction in its use (Bramness et al., 
2012), it remains a key therapeutic for treatment of acute low back pain (Witenko et al., 2014).   
Even with its recent scheduling, a quick internet search reveals a number of pharmacies noting the 
ready availability of carisoprodol without a prescription.  Thus the potential for continuing abuse 
of carisoprodol remains.  Considering a significant proportion of its effect are likely attributable to 
its metabolite meprobamate, the focus of the present study was thus to gain greater insight into 
meprobamate modulation of its major therapeutic target, the GABAA receptor. 
Our assessment of meprobamate’s ability to directly gate and allosterically modulate the 
GABAA receptor is comparable to that reported in neurons (Rho et al., 1997), in that both effects 
are of relatively low potency.  Rho et al. (1997) further categorized its actions as “barbiturate-like”, 
and carisoprodol also displays barbiturate-like effects both in vivo and in vitro (Gonzalez et al., 
2009b). We conducted a number of experiments to better understand the extent to which effects of 
meprobamate mimic those of the barbiturate pentobarbital.  The results demonstrate some 
commonality of effect between the two ligands, but in general do not support a common site of 
action for meprobamate and barbiturates.  The barbiturate antagonist bemegride reversibly and 
significantly inhibited meprobamate-mediated direct gating current in a concentration-dependent 




a mutation (W328M) that conferred sensitivity to pentobarbital (Amin, 1999) did not confer 
sensitivity to meprobamate. In addition, whereas pentobarbital could directly gate homomeric β3 
receptors, this effect was not observed with meprobamate. Thus, whereas a number of in vivo and 
in vitro actions of meprobamate are in fact similar to those observed with pentobarbital, the 
comparison cannot be extended to indicate a common binding domain for these ligands.  In this 
regard, meprobamate is comparable to carisoprodol (Gonzalez et al., 2009b).  Recent photoaffinity 
labeling studies have provided considerable evidence that barbiturates bind to inter-subunit 
interfaces in GABAA (Chiara et al., 2013) and nicotinic (Hamouda et al., 2014) receptors.  With 
regard to GABAA receptors, a photoreactive barbiturate binds to a number of residues at both the 
 and  interfaces in the transmembrane domain (Chiara et al., 2013).  Our current results 
suggest it unlikely that meprobamate would interact with those residues.  
It has become increasingly clear in recent years that many therapeutic and adverse actions 
of GABAergic drugs associate predominantly with particular subunits of the GABAA receptor 
(Low et al., 2000; Crestani et al., 2001; Crestani et al., 2002; van Rijnsoever et al., 2004; Licata et 
al., 2008; Tan et al., 2010; Rudolph et al., 2014).  Of particular relevance to the current study is the 
fact that 2- and 3 expressing receptors are involved in both anxiolytic (Low et al., 2000; Crestani 
et al., 2001; Licata et al., 2008) and muscle-relaxing (Crestani et al., 2001; Griebel et al., 2003) 
effects of GABAergic ligands, while abuse potential associates with the 1 subunit (Licata et al., 
2008; Tan et al., 2010). Our recent report (Kumar et al., 2015) shed some light on the subunit-
dependent effects of carisoprodol itself and how they may relate to its therapeutic and advserse 
effects.  To fully understand actions of carisoprodol, it is necessary to also understand potential 
subunit-dependent effects of the primary and comparatively long-lived metabolite, meprobamate.  
At the maximal concentration assessed, meprobamate-gated current was of similar magnitude in 
α1-, α2-, α4-, α5- and α6β2γ2s GABAARs, and significantly less in α3-expressing receptors.  The 




al., 2015).  With regard to allosteric modulation, carisoprodol displayed considerably greater 
efficacy in α1-expressing receptors (Kumar et al., 2015), whereas meprobamate displayed generally 
similar effects regardless of  subunit, with some enhanced efficacy in 5-expressing receptors.   
The lack of effect of   subunit isoform on direct gating or allosteric effects of meprobamate 
contrasts with carisoprodol, in which direct gating was most efficacious in 1-expressing receptors, 
and allosteric modulation was greatest in 2-expressing receptors (Kumar et al., 2015).  In addition, 
whereas the γ subunit did not have an effect on direct gating or allosteric modulation of carisoprodol 
(Kumar et al., 2015), its presence quite markedly attenuated the modulatory capacity of 
meprobamate.  This effect may not be therapeutically significant as few native receptors express 
only  and  subunits, but it may prove useful in identifying critical domains for effects of 
meprobamate.    
Ligands that influence the actions of GABA may also act at extrasynaptic GABAA 
receptors, which include α4β3δ and α1β3δ subtypes; these receptors have been implicated in 
diseases such as schizophrenia, depression and epilepsy (Brickley et al., 2012). Meprobamate 
directly gated these receptors with an efficacy comparable to that of GABA, which is a partial 
agonist in these receptors (Bianchi et al., 2003). We also observed that GABA’s efficacy was about 
2/3 that of the full agonist THIP in δ subunit-expressing receptors.  Barbiturates (Feng et al., 2004), 
neurosteroids (Wohlfarth et al., 2002) and the parent drug carisoprodol (Kumar et al., 2015) all 
have the ability to enhance the actions of a saturating concentration of GABA in extrasynaptic 
receptors.  We observed a similar effect of meprobamate in the present investigation.  Whereas a 
portion of the peak GABA current enhancement could be attributable to some direct action of 
meprobamate, the majority of the enhancement may relate to shifting of GABA from a low efficacy 
to high efficacy ligand (Bianchi et al., 2003).     
In considering where on the receptor meprobamate acts, key questions include: 1) is the 




at distinct sites for gating and allosteric effects? When initiating these studies, we hypothesized that 
the two ligands act at the same site for both effects.  As noted, experimental evidence has shown 
that both carisoprodol and meprobamate allosterically modulate, directly gate and inhibit the 
GABAA receptor.  Both ligands also display similar actions at -expressing receptors.  Specifically 
with regard to question 1 above, we consider here both direct and allosteric effects.  Results for 
direct gating studies demonstrate the subunit-dependent profile for the two ligands are quite similar, 
and the main difference between the two ligands is potency.  These data are consistent with a single 
overlapping site of action. The isopropyl group of carisoprodol may enhance hydrophobic 
interactions that result in its enhanced potency.  In considering allosteric modulatory effects of the 
two ligands, the subunit-dependent profile showed significantly more variability than that observed 
for direct gating effects.  The influence of  and  subunits was different for meprobamate 
compared to carisoprodol.  Although a definitive conclusion is not warranted, the data are 
consistent with only modestly overlapping or possibly distinct sites for allosteric effects of 
meprobamate, compared to carisoprodol.  Further studies are required to more definitively address 
this issue.                   
In considering whether the direct and allosteric effects of meprobamate are mediated via 
one or two sites, the possibility of two sites is likely.  With regard to carisoprodol, separate sites 
for direct gating and allosteric modulatory effects have been proposed (Kumar and Dillon, 2015).  
As with carisoprodol, the subunit-dependent profiles for direct and allosteric effects of 
meprobamate are distinct.   Additional evidence suggestive of distinct sites comes from recent 
mutagenesis studies.  We have reported in abstract form (Kumar et al., 2013) the fact that amino 
acid mutations in transmembrane domain IV of the  subunit impact direct gating of carisoprodol, 
but have no significant effect on its allosteric actions.  Unpublished results of effects of these 
mutations on the actions of meprobamate suggest a similar effect.   Whether the amino acid residues 




known.  Nevertheless, the fact that the mutations had effects only on direct gating is consistent with 
the conclusion that distinct sites exist for direct and allosteric modulatory effects for both 
meprobamate and carisoprodol. 
Our results provide additional insight regarding the therapeutic and abuse-facilitating 
effects of carisoprodol.   Both carisoprodol and meprobamate display direct gating and allosteric 
modulatory effects on GABAA receptors across the spectrum of expressing receptors, which 
supports physical dependence and abuse potential (Licata et al., 2008). Both ligands effectively 
modulate α2-, α3- and α5-expressing receptors, which provides an effective muscle relaxant profile 
(Crestani et al., 2001; Griebel et al., 2003.  Drawing further from an understanding of 
benzodiazepines, the considerably higher efficacy (and potency) of carisoprodol for allosteric 
enhancement of α1-expressing receptors would seem to be a key contributor for its abuse and 
addictive potential (Licata and Rowlett, 2008; Tan et al., 2010).  In addition, in a study of impaired 
and unimpaired drivers, blood concentration of carisoprodol, but not meprobamate, correlated with 
driver impairment (Bramness et al., 2004).  The authors concluded that carisoprodol itself has 
impairing effects.  As sedative effects are strongly associated with activity at 1-expressing 
receptors, our finding that meprobamate has considerably reduced effects at these receptors, 
compared to carisoprodol, provides a molecular basis in support of the conclusion of Bramness et 
al. (2004).  Meprobamate itself has important limitations as a therapeutic; hence its classification 
as a scheduled drug decades ago.  However, as meprobamate strongly modulates α5-expressing 
receptors (consistent with muscle relaxant effects), and has comparatively inefficient ability to 
modulate α1-expressing receptors (associated with dependence and abuse potential), a re-
evaluation of meprobamate for possible modification is warranted.    
During the time period both meprobamate and carisoprodol were being widely prescribed, 
an extensive series of derivatives of them was generated (Ludwig et al., 1969).  Many of these 




loss of righting reflex) compared to both carisoprodol and meprobamate, as well as an enhanced 
safety margin.  It appears none of these molecules made it to market.  Whether they failed for safety 
or other reasons, or whether the decision to abandon this series of compounds was made in light of 
the subsequent scheduling of meprobamate is not known.  Considering the availability of improved 
assays and our current understanding of molecular pharmacology associated with therapeutic 
effects, it might prove worthwhile to re-assess a number of these meprobamate-related carbamate 
molecules for myorelaxant and other indications.        
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Table 1.  GABA sensitivity of the GABAA receptor subunit configurations studied.  EC50 



















     EC50 (µM) n 
α1β2 16.4 ± 2.39 5 
α1β2γ2 28.6 ± 2.75 8 
α2β2γ2 32.8 ± 1.81 5 
α3β2γ2 34.8 ± 2.09 8 
α4β2γ2 5.9 ± 0.16 5 
α5β2γ2 0.8 ± 0.23 4 
α6β2γ2 1.7 ± 0.24 4 
α1β1γ2 15.7 ± 0.15 7 














Figure 1.  Structure of meprobamate and a prominent parent molecule, carisoprodol.  
The molecules differ by an isopropyl present on one of carisoprodol’s carbamyl nitrogens; the 











































Figure 2. Assessment of subunit-dependent effects of meprobamate on direct activation 
of GABAA receptors. A, Representative traces demonstrating direct activation by 
meprobamate in α1β2γ2, α3β2γ2, α1β2 and α1β1γ2 receptors.  B, C and D, summary data of 
meprobamate mediated direct-gating effects associated with varying  and  subunits, 
respectively.  Direct activation capability was diminished in α3β2γ2 compared to the other 
configurations, whereas varying the  subunit or deleting the 2 subunit had negligible effects.  
Each data point represents the mean ± S.E.M. of a minimum of 4 cells. *,  p < 0.05; **, p < 

































































































































































































































Figure 3. Assessment of subunit-dependent effects of allosteric modulatory effects of 
meprobamate on GABAA receptors. A, Representative traces demonstrating direct allosteric 
potentiation by meprobamate of GABA-gated (EC20) currents in α1β2γ2, α3β2γ2, α1β2 and 
α1β1γ2 receptors.   B, C and D, summary data of allosteric effects of meprobamate associated 
with varying  and  subunits, respectively.  Allosteric potentiation was present in all  
receptors, but greatest in those expressing the 5 subunit; absence of the  subunit also resulted 
in enhanced potentiation.  Note for this and other figures assessing allosteric modulation, 
underlying direct gating effects were subtracted out for calculation of summary data.  Each 


























































































































































































Figure 4. Assessment of direct gating effects of meprobamate in extrasynaptic GABAA 
receptors. A, representative traces demonstrating meprobamate direct gating action on α4β3δ 
and α1β3δ GABAA receptors, in comparison to a saturating concentration of GABA. The 
maximal efficacy of meprobamate was comparable to that of GABA. B, Summary data 
illustrating the efficacy of meprobamate compared to GABA in α1β2, α1β2γ2, α1β3δ and 
α4β3δ GABAA receptor. Data for α1β2 and α1β2γ2 receptors are re-plotted from Figure 1 for 
comparison.  Efficacy of the full agonist THIP was also assessed; it was significantly more 
efficacious than either GABA or meprobamate on δ-containing GABAA receptors.  Each bar 
represents the mean ± S.E.M. of a minimum of 3 cells for δ-containing receptors, and mean ± 


















































































































Figure 5. Assessment of allosteric effects of meprobamate in extrasynaptic receptors.  A, 
representative traces demonstrating the potentiation by meprobamate of GABA-gated (EC20) 
currents in α4β3δ GABAA receptors. B, Bar graph summarizing the concentration-response 
profile for the allosteric modulatory effects of meprobamate on extrasynaptic α4β3δ GABAA 

















































































Figure 6.  Potentiation of maximal GABA by meprobamate in extrasynaptic receptors. 
A, Illustrative traces showing that in both α4β3δ and α1β3δ extrasynaptic GABAA receptors, 
1 mM meprobamate significantly enhanced the magnitude of a saturating concentration of 
GABA alone, whereas this potentiation was not observed in α1β3 or α1β2γ2 receptors.   B, 
Summary data illustrating potentiation of maximal GABA current by both pentobarbital and 
meprobamate in δ-subunit expressing receptors, compared to those not expressing the δ 
subunit. Data are expressed relative to the peak current amplitude elicited by saturating 
concentration of GABA. Each bar represents the mean ± S.E.M. of a minimum of 3 cells for 































































)    1  3 
   1  3  2 
   1  3  
   4  3  
** 








Figure 7. Assessment of “barbiturate-like” actions of meprobamate. A, top, representative 
traces demonstrating meprobamate-activated currents are reversibly reduced in the presence of 
the barbiturate antagonist bemegride in stably expressed human α1β2γ2 receptors. A, middle, 
Neither pentobarbital nor meprobamate could directly gate wild type homomeric ρ1 receptors; 
the W328M mutation conferred sensitivity to pentobarbital, but not meprobamate. A, bottom, 
Pentobarbital directly gated homomeric 3 receptors, whereas meprobamate blocked the 
spontaneously open current present in these channels.  B, Summary results for experiments 
presented in panel A.  Each data point represents the mean ± S.E.M. of a minimum of 4 cells 
for all data sets.   *,  p < 0.05; **, p < 0.01;  ***, p < 0.001; #, p < 0.05 compared to the 3 mM 
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Meprobamate (tradenames Miltown, Equanil) is a schedule IV anxiolytic and the primary 
metabolite of the muscle relaxant carisoprodol. Though it used to be a widely prescribed 
tranquilizer, a thorough understanding of its direct-gating, allosteric-modulation and inhibitory 
effects remains ill-defined. Meprobamate modulates GABAA (γ-aminobutyric acid type A) 
receptors, and has been described as having a barbiturate-like activity.  In previous reports, we 
found that in comparison to α1β2γ2 receptors, α3β2γ2 receptors had attenuated direct gating 
effects for both meprobamate and carisoprodol. Here, using site-directed-mutagenesis and 
whole cell patch clamp electrophysiology in transiently transfected HEK293 cells, we 
examined the role of GABAA receptor α-subunit transmembrane domain 4 (TM4) amino acids 
in direct gating actions of meprobamate, and transmembrane domain 2 (TM2) amino acids in 
inhibitory actions of meprobamate and carisoprodol. Mutation of α3 valine at position t440 to 
leucine (present in the equivalent position in the α1 subunit) increased the direct gating potency 
and efficacy of meprobamate. In α1β2 heteromeric GABAA receptors, both pentobarbital and 
carisoprodol had inhibitory effect for allosteric modulatory action at higher concentrations. 
Meprobamate did not have an inhibitory effect at the concentrations tested. T6’F mutation of 
the β2-subunit abolished the inhibition of carisoprodol but not of pentobarbital. Thus, our 
studies provide further insight into molecular determinants of actions of meprobamate, its 
parent drug carisoprodol and their comparison to barbiturate pentobarbital. 








GABAA receptors are members of cys-loop ligand-gated ion channel superfamily. 
Other members of this group are glycine, acetylcholine receptor, GABAC receptors, serotonin 
(5HT-3) receptors (Sine et al., 2006). GABAA receptors are the primary inhibitory receptors 
of the CNS (Bormann, 2000). Upon activation, opening of chloride channels and chloride ion 
entry, lead to the development of inhibitory post-synaptic potential (IPSP) (Bormann, 2000).  
GABAA receptors are pentameric in nature. Each of the subunits are composed of a 
long extracellular N-terminal domain, a short C-terminal domain, 4 transmembrane domains 
(TM1-TM4), an extracellular TM2-TM3 loop and two intracellular loops, a large TM3-TM4 
and a short TM1-TM2 loop (Cockcroft et al., 1995). TM2 of all the 5 subunits make the pore 
of the channel (Xu et al., 1996; Miyazawa et al., 2003). Some inhibitors of GABAA receptors 
interact with amino acids constituting TM2 loop (Gurley et al., 1995). GABAA receptors are 
seats of action of many inhibitory ligands like benzodiazepines, barbiturates, neuro-steroids 
and muscle relaxants like carisoprodol and meprobamate (Gonzalez et al., 2009b; Rudolph et 
al., 2011; Kumar et al., 2015) 
Meprobamate, used to be a widely prescribed tranquilizer, anti-convulsant and muscle 
relaxant (Hendley et al., 1954; DeLong et al., 1985). Within few years of its introduction, cases 
of abuse and physical and psychological dependence started piling up (Ewing et al., 1957). So 
it was made a controlled substance (schedule IV) at the federal level. While meprobamate was 
made a controlled substance, drugs metabolized to meprobamate are widely available. One 
such drug is the muscle relaxant carisoprodol whose easy availability due to internet 
pharmacies, has made it a widely abused drug (Toth et al., 2004; Sullivan, 2015). There have 
been many cases of abuse, dependence and in some cases even death due to carisoprodol 




2003; Zacny et al., 2011; Zacny et al., 2012). Although carisoprodol can have independent 
action (Gonzalez et al., 2009b), a significant portion of its action and abuse is due to 
meprobamate. As much of the research done on meprobamate has been in the years prior and 
during its major use, its detailed mechanism of action is not clear. It was shown to act on 
GABAA receptors in a barbiturate like manner (Rho et al., 1997). Our lab has shown 
meprobamate to have both direct-gating and allosteric modulatory effect on all synaptic and 
extra-synaptic GABAA receptors subunit combinations. For direct-gating, meprobamate and 
carisoprodol, had maximum effect on α1 containing receptor while α3 had the least effect 
(Kumar et al., 2015)(Kumar et al. 2016, in press). TM1-TM3 are fully conserved between α1 
and α3 subunits. However, amino acids I419, I423 and V440 of TM4 of α3 are different from 
that of α1 subunit (Barnard et al., 1998; Bergmann et al., 2013). Here we tested the hypothesis, 
how this difference in the amino-acid compositions between α3 and α1 is responsible for the 
difference in the direct gating actions on the two subunits. 
High concentrations of carisoprodol and pentobarbital had inhibitory effects for 
allosteric modulatory action in GABAA receptor. TM2 T6’ residue of the β-subunit of glycine 
receptor, has been implicated in the blocking action of picrotoxin (Pribilla et al., 1992). Later 
it was also shown to be critical in the picrotoxin blocking action in GABAA (Gurley et al., 
1995)and ρ1 GABAC receptors (Zhang et al., 1995). T6’F mutation has been known to cause a 
significant reduction in picrotoxin inhibitory effect without abolishing it completely (Shan et 
al., 2001; Sedelnikova et al., 2006). This residue has been shown to be involved in blocking 
effects of other ligands of GABAA receptors. We tested the hypothesis that T6’ residue is also 






2. Materials and Methods 
2.1 Cell Culture and Transfection  
Human embryonic kidney 293 (HEK293) cells transiently expressing varying GABAA 
receptor subunits, were used in the present study.  For transient transfection, cells were 
transfected with human GABAA α; human β; and human γ2s (short isoform) cDNA in a 1:1:5 
ratio (2 µg total cDNA) using PolyJetTM in vitro transfection reagent (SignaGen Laboratories, 
Jamesville, MD). The γ2s subunit will be referred to as γ2 from here forth. Human GABAA 
α1 subunit cDNA was generously provided by Neil Harrison (Columbia University Medical 
Center, New York). Rat α1 and β2 subunits were also used. Transfection using just the α and 
β subunits were made using the plasmids in ratio 1:1 with a total of 2µg of cDNA.  PolyJetTM 
in vitro transfection reagent was used 3µl/µg of DNA. Cells were plated on glass coverslips 
coated with poly-L-lysine in 35-mm culture dishes, and maintained at 37ᵒC in a humidified 
incubator with an atmosphere of 5% CO2 In all cases, cells were used for recording 24-72 
hours after transfection.  
 
2.2 Electrophysiology  
             Whole-cell patch clamp electrophysiology was used to assess GABA-, meprobamate-
or pentobarbital-activated Cl- currents. All electrophysiology experiments were conducted at 
room temperature (22-25 ᵒC) with the membrane potential clamped at -60 mV. Patch pipettes 
of borosilicate glass (1B150F; World Precision Instruments, Inc., Sarasota, FL) were pulled 
(Flaming/Brown, P-87/PC; Sutter Instrument Company, Novato, CA) to a tip resistance of 4–
6MΩ. Patch pipettes were filled with a solution consisting of 140 mM CsCl, 10 mM EGTA-
Na+, 10 mM HEPES-Na+, and 4 mM Mg2+-ATP, pH 7.2. Coverslips containing cultured cells 




superfused continuously with an external solution consisting of 125 mM NaCl, 20 mM HEPES, 
3 mM CaCl2, 5.5 mM KCl, 0.8 mM MgCl2, and 10 mM glucose, pH 7.3. Agonist-induced Cl− 
currents were obtained with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) 
equipped with a CV-203BU headstage. Currents were low-pass filtered at 5 kHz, monitored 
simultaneously on an oscilloscope and a chart recorder (Gould TA240; Gould Instrument 
Systems Inc., Cleveland, OH), and stored on a computer using an on-line data acquisition 
system (pCLAMP 6.0; Axon Instruments) for subsequent off-line analysis. 
 
2.3 Chemicals and solutions 
 Meprobamate, carisoprodol, pentobarbital, diazepam, salts and buffers were purchased 
from Sigma Aldrich (St. Louis, MO). GABA was obtained from Acros Organics (New Jersey, 
US). Stock solutions of meprobamate, pentobarbital and carisoprodol were made using 
dimethylsulfoxide (DMSO).  Drugs were diluted in normal saline, so that the final DMSO 
concentration (vol/vol) of the test solutions was ≤0.3%.  GABA and diazepam stock solutions 
were prepared using de-ionized H2O.  All stock solutions were stored at -20 
ᵒC. On 
experimental days, drug-containing solutions were prepared from stock by serial dilution into 
external solution.  
 
2.4 Experimental Protocol  
GABA (with or without modulatory ligand), meprobamate, carisoprodol or 
pentobarbital were prepared in external solution on the day of use and applied via a 16-barrel 
rapid perfusion system  in which all barrels (200 µm outer diameter quartz tubes; ALA 
Scientific, Folsom, CA) emptied via a common tip positioned adjacent to the cell under study.  
Flow through each barrel was pressure fed and regulated by solenoid or pinch valves operated 




the buffer solution was applied continuously between drug applications via gravity or positive 
pressure. For some experiments, ligands were applied via gravity flow using a Y-tube placed 
adjacent to the cell.  
The modulatory effects of meprobamate, pentobarbital or carisoprodol on GABA-
gated currents were assessed using an EC20 gating concentration of GABA as the control. This 
gating concentration was selected to ensure there was a sufficient range to observe the full 
allosteric potential of meprobamate. To ensure the gating concentration was approximately an 
EC20, control responses were compared to the maximal GABA-gated current for each 
individual cell. On a cell by cell basis, control GABA currents were deemed acceptable for 
assessment of allosteric modulatory effects of meprobamate if they were within a 15-25 % 
range of maximal current for that particular cell.  Control responses were established by 
observing two consecutive agonist-activated currents that varied in amplitude by no more than 
± 10%. In our analyses of the modulatory effects of meprobamate, peak current amplitude was 
defined as the maximum current elicited by GABA.  In all studies assessing direct gating 
effects, the magnitude of the response was expressed relative to the maximal effect of GABA 
(designated 100%).  For αβγ configurations, GABA-gated control currents were recorded in 
the presence of diazepam to confirm incorporation of the γ2 subunit.  
 
2.5 Data Analysis  
             To ensure equipotent concentrations were used for gating, GABA concentration-
response data were collected. From these data, EC20 and saturating GABA concentrations were 
calculated for each configuration and used in subsequent investigations of the allosteric and 
direct effects, respectively.  For studies assessing allosteric actions, a correction was applied 
to subtract underlying direct gating effects.  All data are presented as mean values ± S.E. 




Student’s t-test (paired or unpaired) and one-way analysis of variance. Tukey-Kramer post hoc 
test for multiple comparisons was performed as needed. 
 
2.6 Plasmids and site-directed-mutagenesis  
             Human cDNA plasmids encoding α1, α3, β2 and γ2 GABAA receptor subunits were 
used in the present study. Individual and combined mutations in α3 cDNA plasmids were 
created using Stratagene’s Quik Change II ® site-directed-mutagenesis kit (Agilent 
Technologies; La Jolla, CA) and were sequenced to confirm mutations at West Virginia 






















3.1 TM4 amino acid mutations α3 to corresponding α1, lead to an increased meprobamate 
mediated direct gating effect 
             On testing for the action of meprobamate on various subunit compositions of GABAA 
receptors, we found it to have maximum direct-gating effect on α1 and a significantly 
attenuated effect on α3 containing GABAA receptors. Further we saw the effect of 
meprobamate to be consistent with its action in the transmembrane region (Hosie et al., 2006). 
When we looked for difference in structure, amino-acid compositions of TM1-TM3 regions is 
conserved between α1 and α3 subunit isoforms. TM4 region is also largely conserved, except 
for, I420, I424 and V441 of α3, which differs from α1, which are L420, A424 and L441 
(Barnard et al., 1998; Bergmann et al., 2013) (Fig.1). To test the roles of these amino acids 
unique to α3 in the attenuated direct gating effect, successive mutations were made to convert 
α3 to α1 either singly or in combination, using site directed mutagenesis. Mutations tested 
were, α3 (V441L), α3 (I420L/I424A) and α3 (I420L/I424A/ V441L).  In order to assess the 
receptor function, GABA concentration response was done on each mutants. In general, the 
shift in GABA EC50 was modest (Table 1). We observed an increase in direct gating efficacy 
for meprobamate in mutant receptors compared to WT α3 receptors, suggesting the role of 
above amino acids in different direct gating efficacy of α3 and α1 receptors. 
 
3.2 Carisoprodol and pentobarbital, but not meprobamate show an inhibition and rebound at 




             At lower concentrations (< 100 µM), pentobarb, meprobamate and carisoprodol 
enhanced GABA mediated current in a concentration-dependent manner. At higher 
concentrations (> 100 µM), there was successive attenuation of GABA-mediated current by 
both pentobarb and carisoprodol. At 3 mM a rebound or offshoot was observed on drug 
application termination (Fig 3A and 4A). Neither an attenuation nor rebound was observed 
with meprobamate at the concentrations tested (till 3 mM) (Fig. 5A). We may observe a similar 
effect for meprobamate at higher concentrations as it has shown approximately 3 times less 
sensitivity than carisoprodol in our previous reports. 
 
3.3 T6’F mutation in β2 subunit, attenuates inhibition and rebound (offshoot) currents in 
carisoprodol, but not in pentobarital 
             Lower concentration of both pentobarb and carisoprodol enhanced GABA-mediated 
currents in WT α1β2 GABAA receptor. At concentrations > 100µM, there was progressive 
inhibition and a rebound and offshoot was observed upon drug termination at 3 mM with both 
the ligands. A T6’ amino-acid in the β2 subunit has previously been implicated in inhibitory 
effects of other inhibitory ligands. TM2 T6’ residue of the β-subunit of glycine receptor, has 
been implicated in the blocking action of picrotoxin (Pribilla et al., 1992). Later it was also 
shown to be critical in the picrotoxin blocking action in GABAA receptor (Gurley et al., 1995) 
and ρ1 GABAC receptor (Zhang et al., 1995). T6’F mutation was tested since it has been known 
to cause a significant reduction in picrotoxin sensitivity without abolishing it completely (Shan 
et al., 2001; Sedelnikova et al., 2006). We tested the hypothesis that T6’ residue is implicated 
in the above blocking actions. TM2 T6’ residue, when mutated to T6’F, both inhibition and 




mediated inhibition or rebound. Thus, pentobarbital may have different binding site or 
functional domain for this particular action. Pentobarbital had a direct gating effect in β3 
homomeric receptors. Both meprobamate and carisoprodol, like picrotoxin, blocked 
spontaneously open current in the β3 homomer. This MEP and CSP mediated blockage was 
abolished in homomer with T6’F mutation, unmasking their direct gating effect. Homomer 
with T6’F mutation in β3 subunit, did not affect pentobarbital mediated direct gating current, 


















             Meprobamate was the first widely prescribed tranquilizer agent (DeLong et al., 1985). 
Initially found to be free of side effects in animal studies and in populations using regular 
therapeutic doses (Boyd et al., 1958), many cases of abuse and dependence were observed in 
patients having history of misuse of other drugs and alcohol abuse (Mohr et al., 1958). Also, 
after long term use, cases of physical and psychological dependence started to appear (Lemere, 
1956; Ewing et al., 1957). Thus, it was made a controlled substance and its use started to 
dwindle after the introduction of benzodiazepines (Berger, 1964; Greenblatt et al., 1974). 
Although meprobamate was made a controlled substance, drugs metabolized to meprobamate 
are widely available. One such drug is the centrally acting muscle relaxant carisoprodol (Toth 
et al., 2004; Sullivan, 2015). It is easily available and widely used, especially after the advent 
of internet pharmacies. Many serious cases of abuse, dependence and withdrawal have also 
been reported for carisoprodol (Adams et al., 1975; Elder, 1991; Littrell et al., 1993; Rust et 
al., 1993; Reeves et al., 2003; Zacny et al., 2011; Zacny et al., 2012). Carisoprodol was known 
to act via its metabolite meprobamate, already a controlled substance and without a known 
mechanism of action. Our previous reports have shown carisoprodol itself, independent of 
meprobamate, and meprobamate act on synaptic and extra-synaptic GABAA receptor in a 
subunit dependent manner (Gonzalez et al., 2009b; Kumar et al., 2015). For direct-gating 
actions, meprobamate potency and potentially efficacy, was much higher for α1 expressing 
GABAA receptor compared to α3 expressing GABAA receptor. In this respect, action of 
meprobamate is qualitatively similar to its parent drug carisoprodol, however, the potency of 
this effect is lot less for meprobamate compared to carisoprodol (Gonzalez et al., 2009b; Kumar 




             Activity of meprobamate and carisoprodol suggest a transmembrane-domain specific 
action (Hosie et al., 2006). Upon alignment, there is similar amino-acid compositions in the 
TM1-TM3 region, while TM4 region has 3 different amino-acid composition between α1 and 
α3 subunits. These were I419, I423 and V440 (Barnard et al., 1998; Bergmann et al., 2013). 
To test their role in attenuated direct gating effects of meprobamate at α3, we tested successive 
mutations from α3 to α1 subunit. An increase in direct gating efficacy was observed, suggesting 
the role of these amino acids for the direct-gating actions of meprobamate. A similar gain in 
function was also observed for carisoprodol, though of a much higher magnitude. This shows 
similar domains may be responsible for the direct-gating actions of carisoprodol and 
meprobamate. 
             Further, meprobamate and carisoprodol actions have been described as barbiturate like 
(Rho et al., 1997; Gonzalez et al., 2009b). In our previous reports, we have seen several points 
of similarities and differences in the actions of meprobamate, carisoprodol and barbiturates. 
Supra-potentiation of GABA saturation current seen in δ-containing GABAA receptors was 
also observed with carisoprodol and meprobamate. Mice trained to identify carisoprodol also 
identified meprobamate and pentobarbital. Barbiturate-antagonist, bemegride, reversibly 
inhibited meprobamate and carisoprodol mediated currents (Gonzalez et al., 2009b)(Kumar et 
al., 2015, in press). Also in ρ1-homomeric receptor, natively found in retina, meprobamate, 
carisoprodol and barbiturate pentobarbital, did not have any direct effect. However, a W328M 
mutation in ρ1, salvaged pentobarbital mediated current, but not that of carisoprodol and 
meprobamate (Gonzalez et al., 2009b)(Kumar et al., 2015, in press). Also in β3 homomeric 
receptors pentobarbital had a direct-gating action whereas meprobamate had an inhibitory 




             In this study we used α1β2 hetero-pentamer to test for inhibitory actions of 
carisoprodol, meprobamate and pentobarbital. At lower concentrations (< 100 µM), all three 
enhanced GABA mediated current. However at higher concentrations, an inhibition was 
observed with pentobarbital and carisoprodol. At 3 mM, a rebound current was observed upon 
termination of both pentobarbital and carisoprodol. Meprobamate continued to enhance GABA 
mediated current at concentrations tested (3mM). One reason could be the lower sensitivity of 
meprobamate compared to carisoprodol (approximately one third of carisoprodol). We may 
see a similar phenomenon at higher concentrations. T6’ of β2 is found in the TM2 region (pore 
region) and has been implicated in the inhibitory effect of picrotoxin (Pribilla et al., 1992; 
Gurley et al., 1995; Zhang et al., 1995). We tested whether this amino acid is responsible for 
the inhibitory effects observed with the two ligands as T6’F mutation has been shown to abolish 
picrotoxin mediated inhibition (Shan et al., 2001; Sedelnikova et al., 2006). T6’, mutated to 
T6’F, abolished the inhibitory and rebound effects of carisoprodol but not of pentobarbital. 
This suggests T6’ residue responsible for the inhibitory effect of carisoprodol but not of 
pentobarbital. At the concentrations tested, meprobamate did not show an inhibitory effect. 
Taken together these findings suggest a distinct sight for inhibitory actions for barbiturates 
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Table III-1. Influence of GABAA receptor α3 TM4 amino acids mutation to 
corresponding α1 amino acids on GABA EC50 values Each data point represents the mean 





























  GABA 
   EC50 (µM) 
           n 
MEP gating 




α3 WT 34.8 ± 2.1 6 7.25 ± 2.8 5 
α3(V440L) 07.5 ± 0.9 ** 7 13.25 ± 1.89 3 
α3(I419L/I423A) 18.1  ± 2.2* 9 12 ± 4 3 
α3(I419L/I423A/V440L) 15.8  ± 5.0 * 6 8 ± 2.65 3 
α1 WT 28.6 ± 2.75 8 32 ± 8.1 5 
     
     
     
     
















Figure 1. Alignment of α1 and α3 domains of TM4 showing non-identical (red) and mutated 














































Figure 2. Influence of the alpha3 subunit TM4 mutations on direct activation by 
meprobamate.  A, representative traces demonstrating carisoprodol and meprobamate activate 
human 3(V441L) 22 GABAARs.  B, bar graphs summarizing meprobamate direct gating 
currents for human α3-, α3 (V441L)-, α3 (I420L/I424A/V441L) and 122 GABAARs. **, 


































































































Figure 3. Influence of β-subunit TM2 T6’F Mutation on inhibitory effects of carisoprodol. 
A) Representative traces from R-α1β2 GABAA receptor demonstrating modulation of GABA-
gated currents by carisoprodol. At high concentrations, currents are inhibited and offshoot 
currents are observed upon termination of drug application. This phenomenon is attenuated 
with α1β2 (T6’F) GABAA receptor. B) Low concentration CSP potentiated the GABA gated 
current of both R-α1β2 GABAA receptor and R-α1β2 (T6’F) GABAA receptor. High 
concentration of CSP inhibit R-α1β2 receptors but in R-α1β2 (T6’F) receptors, inhibitory effect 









































































Figure 4. Influence of β-subunit TM2 T6’F Mutation on inhibitory effect by 
pentobarbitol. A) Representative traces from R-α1β2 GABAA receptor demonstrating 
modulation of GABA-gated currents by pentobarbital. At high concentrations, currents are 
inhibited and offshoot currents are observed upon termination of drug application. A similar 
phenomenon is observed with α1β2 (T6’F) GABAA receptor. B) Low concentration PB 
potentiated the GABA gated current of both R-α1β2 GABAA receptor and R-α1β2(T6’F) 
GABAA receptor. High concentration of PB inhibit R- α1β2 receptors but in R-α1β2(T6’F) 
receptors, inhibitory effect was not attenuated unlike CSP. Each bar represents the mean ± S.E. 

































































Figure 5. Influence of β-subunit TM2 T6’F Mutation on allosteric modulation by MEP. 
A) Representative traces from R-α1β2 GABAA receptor demonstrating modulation of GABA-
gated currents by MEP. At high concentrations, no offshoot currents are observed upon 
termination of drug application and currents are not inhibited as seen with CSP or PB. A similar 
phenomenon is observed with α1β2 (T6’F) GABAA receptor. B) Low concentration MEP 
potentiated the GABA gated current of both R-α1β2 GABAA receptor and R-α1β2 (T6’F) 
GABAA receptor. High concentrations of MEP do not inhibit R-α1β2 or R-α1β2 (T6’F) 









































































































SUMMARY, DISCUSSION AND FUTURE DIRECTIONS 
             Meprobamate was the first drug to be prescribed purely as a tranquillizer, that is, 
capable of allaying anxiety without inducing sedation or sleep (DeLong et al., 1985). It was a 
wonder drug when introduced and sold billions of pills. With therapeutic doses, it did not 
produce addiction or dependence, even after prolonged use (Boyd et al., 1958). Higher than 
normal dose, in patients with history of other drugs or alcohol abuse, led to all the 
characteristics of a habit forming drug. These include an intense craving for the drug based on 
its euphoric effect, tolerance build up, requiring increasingly larger doses to produce the same 
effect, and withdrawal symptoms associated with sudden discontinuation of the drug (Lemere, 
1956; Mohr et al., 1958). Considering increasing number of cases of physical and 
psychological dependence, meprobamate was made a controlled substance (Greenblatt et al., 
1971; Hollister, 1983). While meprobamate is a controlled substance, drugs metabolized to 
meprobamate are widely and easily available, and abused. One such drug, carisoprodol, is a 
widely prescribed centrally acting skeletal muscle relaxant (Toth et al., 2004; Sullivan, 2015). 
It is most commonly used for short term allaying of skeletal muscle pain and discomfort. 
Carisoprodol use has been characterized by quick development of tolerance, leading to use of 
increasing doses to produce the desired effect. After long term use of high dose of carisoprodol, 
strong withdrawal symptoms have been observed. These include delusion, seizure and even 
death (Adams et al., 1975; Elder, 1991; Littrell et al., 1993; Rust et al., 1993; Reeves et al., 
2003; Zacny et al., 2011; Zacny et al., 2012). Considering the dangers posed by the abuse of 
carisoprodol, it was made a scheduled 4 controlled substance at the federal level in January 
2012 by the United States Drug Enforcement Administration. Considering present and 
potential danger posed by carisoprodol use and abuse, it was of utmost importance to know its 




which lacks the isopropyl group found in carisoprodol. Meprobamate is already a controlled 
substance, but its detailed mechanism of action is also unknown. 
             It has been shown that the therapeutic and adverse effects of GABA ligands depend 
upon their interactions with the GABAA receptor subunits (Ito et al., 1996; Ator, 2005; Licata 
et al., 2005; Wafford, 2005; Olsen et al., 2008). α2 containing GABAA receptors have the 
anxiolytic and, to a large extent, myorelaxant actions; and the α3- and α5-containing GABAA 
receptors, have the myorelaxant actions. Moreover, tolerance to the sedative action has been 
linked to α5-containing GABAA receptors, and their addictive properties to α1-containing 
GABAA receptors (Low et al., 2000; McKernan et al., 2000; Crestani et al., 2001; Crestani et 
al., 2002; Rudolph et al., 2004; van Rijnsoever et al., 2004; Tan et al., 2010).  In addition, 
physical dependence is more likely to develop with drugs that interact with a broader collection 
of GABAA receptor subtypes
 and misuse of agents that directly gate the receptor is more likely 
to result in fatal complications than those that only allosterically enhance receptor activity 
(Licata et al., 2008; Fass, 2010). So we tested for detailed subunit dependent action of 
carisoprodol on GABAA receptor, but in order to understand a complete pharmacological 
profile of this widely used and abused drug, we also set out to understand the complete subunit 
dependent action of its metabolite, meprobamate. The only knowledge regarding the action of 
meprobamate was its interaction in a barbiturate like manner with GABAA receptors. So, we 
also set out to chalk out the difference between the action of meprobamate and barbiturate 
pentobarbital.              
              We found meprobamate to have direct gating, allosteric modulatory and inhibitory 
actions on various synaptic and extra-synaptic GABAA receptors. For direct gating, α1 had 
significantly more efficacy than α3 containing receptors. To understand the molecular basis for 




several amino-acids of difference between the two subunits in the TM4 region. Using site 
directed mutagenesis, amino-acids from α3 were converted to those in α1 either singly or in 
combination. We found a gain in function, suggesting these amino-acids to be responsible for 
attenuated α3 direct gating action. A similar gain in function was also observed for 
carisoprodol, however of a much higher magnitude. Structural difference between carisoprodol 
and meprobamate is minimal. Both are propanediol bicarbamate, with carisoprodol having an 
isopropyl group, absent in meprobamate.              
             For allosteric modulatory action of meprobamate, α5 subunit was somewhat more 
efficaceous compared to other subunits. In carisoprodol, α1 subunit was significantly more 
potent and efficacious than other subunits. Also, carisoprodol potency on all the subunits, was 
more than meprobamate. So for allosteric-modulatory actions, a difference in potency and  
subunit preferring effect was observed.  
             Effects of β and γ subunits were also tested for direct gating and allosteric modulatory 
effects. γ subunit did not have any influence on both these effects of carisoprodol. While for 
meprobamate, γ subunit did not influence the direct gating but had a significant inhibitory 
effect for allosteric-modulation. β subunit had an effect on both the direct gating and allosteric 
modulation of carisoprodol. β1 subunit had significantly more direct-gating effect compared 
to β2 while β2 had significantly more allosteric-modulatory effect compared to β1. β-subunit 
did not influence either meprobamate direct gating or allosteric modulation. The above 
differences may be exploited to know about the critical domains responsible for the action of 
meprobamate and carisoprodol. 
             Extra-synaptic GABAA receptors represented by α4β3δ and α1β3δ were also tested. 




this respect, actions of both carisoprodol and meprobamate were barbiturate like. For direct 
gating action on the extra-synaptic receptors, both carisoprodol and meprobamate were almost 
as much efficacious as GABA. Both meprobamate and carisoprodol also had allosteric-
modulatory effects on the extra-synaptic receptors. 
             Further comparison with the barbiturates was done using ρ1 homomeric receptors 
found natively in retinal ganglion cells and β3 homomeric receptors, not found natively. All 
three, meprobamate, carisoprodol and pentobarbital did not have a direct gating action on ρ1-
homomeric receptors. A mutation W328M, however, salvaged the direct gating action of 
pentobarbital, but not of carisoprodol or meprobamate. For β3-homomeric GABAA receptors, 
barbiturate pentobarbital had an agonist effect while meprobamate, blocked the spontaneously 
open current, a mechanism followed by picrotoxin, a known GABA inhibitor. A T6’F mutation 
in β3 subunit abolished the meprobamate mediated inhibition, without affecting the 
pentobarbital mediated direct gating.  
         In receptors formed by α1β2, allosteric actions of meprobamate, carisoprodol and 
pentobarbital were tested. Meprobamate, at tested concentrations (maximum 3 mM), 
continuously potentiated GABA mediated current in a concentration dependent manner. At 
lower concentrations (< 100µM), carisoprodol and pentobarbital potentiated GABA gated 
currents in a concentration dependent manner but at higher doses, showed an inhibition and a 
rebound at 3mM. T6’ residue in β-subunit TM2 region (pore forming region) when mutated to 
T6’F, attenuates the inhibition and abolishes the rebound in carisoprodol, but not pentobarbital. 
Thus 6’ residue seems to be involved in the inhibitory actions of carisoprodol, but not 
pentobarbital. At concentrations tested, meprobamate did not show an inhibitory action in α1β2 
receptors. Meprobamate may show an inhibitory and rebound effect on testing at higher 




our previous reports. In β3 homomeric receptor both meprobamate and carisoprodol block 
spontaneously open current. A T6’F mutation abolishes this action for both carisoprodol and 
meprobamate and unmask their direct gating effect.   So the β3 actions represent a similarity 
of action of meprobamate and carisoprodol, representing a similar binding site/or functional 
domain for this particular action, between carisoprodol and meprobamate. Pentobarb has an 
agonist action at β3 homomeric receptors representing a different binding site/functional 
domain than both meprobamate and carisoprodol.  
          In an effort towards drug development, we need to further explore the mechanism of 
actions of meprobamate. We saw a gain in function for the direct action from α3 to α1 
conversion mutations in the TM4 region. We need to test the same for the reverse mutations 
from α1 to α3 and observe whether there is a loss of function. A similar study conducted for 
carisoprodol, showed leucine residue at position 415 of α1 subunit to be responsible for its 
direct gating action. The combination of the above two studies would help us to identify the 
amino acids responsible for the direct gating actions of the meprobamate.  
             An important study would be to identify the property of the amino-acids responsible 
for the direct gating action. For this, amino-acid identified for the direct gating action shall be 
mutated to various other amino acids with varying size, charge, hydrophoebicity or polarity. A 
correlation observed between the magnitude of the current and a particular property would help 
us identify that particular property to be responsible for the direct gating. For carisoprodol, at 
position 415, volume and polarity of the amino acids have been shown to be associated with 
its direct gating efficacy. A similar study shall be undertaken to find the binding domain and 
property of the amino acids responsible for the allosteric modulation. Above amino acids did 




understanding of the domains responsible for the binding pocket for direct gating and allosteric 
modulatory action, we shall also take resort to molecular modeling techniques.  
          Further, allosteric modulatory actions of general anesthetics etomidate, propofol and 
isoflurane have shown voltage dependence (O'Toole et al., 2012). Parent drug of meprobamate, 
carisoprodol has also shown voltage dependent allosteric modulatory actions but not direct 
gating action (Kumar et al., 2015). Again showing a different binding sites for carisoprodol for 
direct gating and allosteric modulatory effects and thus multiple binding sites for carisoprodol 
at GABAA receptor. It would be interesting to see whether meprobamate mediated actions also 
show voltage dependence.   
          We are still not sure whether the amino acid identified via the mutation studies 
participate in the direct binding or carry the wave of conformational changes, a mechanism 
called coupling. Substituted cysteine accessibility method would help us to differentiate 
between the two. The substituted-cysteine accessibility method (SCAM) provides an approach 
for identifying the amino acid residues that line channels , transporters, or binding-site crevices 
in membrane-spanning proteins (Chen et al., 1997; Javitch et al., 1998; Dodd et al., 2005). 
SCAM can also be used to investigate structural alterations in membrane-spanning segments 
in different functional states of proteins. Sulfhydryl group of native or engineered cysteine of 
a protein can be at water accessible surface, lipid accessible surface or a protein interior. Rate 
of reaction of a hydrophilic reagent would be much faster with an ionized sulfhydryl group (at 
water accessible region) than a non ionized sulfhydryl group. Measuring the rate of change of 
reaction of an engineered cysteine with a hydrophilic reagent in presence or absence of a ligand 
can help us conclude the movement of the particular amino acid (and thus the loop) in presence 




           It has become increasingly clear in recent years that many therapeutic and adverse 
actions of GABAergic drugs associate predominantly with particular subunits of the GABAA 
receptor. This has been studied extensively in animal models in which a particular subunit is 
deleted and resultant absence of a particular effect is attributed to the deleted subunit. This 
technique has been used to show the subunits responsible for alcohol tolerance, dependence, 
consumption and taste aversion (Barnard et al., 1998; Jacob et al., 2008; Miller et al., 2014; 
Whissell et al., 2015). A role for extrasynaptic receptors have also been attributed for alcohol 
consumption using similar techniques (Feusner et al., 2001). Knockout mice have also been 
used for assessing therapeutic and abuse potentials for benzodiazepines (Rudolph et al., 2011). 
Our study demonstrates that meprobamate action in-vitro depends upon GABAA receptor 
subtype isoforms. A further testing of our findings in in-vivo model in the knockout mice would 
further confirm actions of meprobamate on the tested subunits and help us better predict subunit 
dependent effects of meprobamate. 
          Meprobamate has both tranquilizing and muscle relaxing properties. An initial effort was 
made by Berger for preparation of compounds for the separation of the above two activities. In 
this effort many compounds chemically related to meprobamate were prepared and subjected 
to pharmacological evaluation (Berger et al., 1960). From the chemical formula of 
meprobamate, 2-methyl-2-propyl-1, 3-propanediol dicarbamate, the N-substituted and N-
nonsubstituted compounds were tested for muscle relaxant, anti-convulsant and toxic actions. 
N-isopropyl-2-methyl-2-propyl-1, 3-propanediol dicarbamate, or carisoprodol showed a 
promising muscle relaxant action alienated from tranquilizing action of meprobamate (Berger 
et al., 1960). Carisoprodol was further tested and made available for medical use. One reason 
CSP was further evaluated was its proximity to the structure of meprobamate which was widely 




not many compounds could have been tested at that time. However many compounds generated 
showed a promising muscle relaxant and anti-convulsant profile. Chemical groups commonly 
tested were 3-propanediols; 1, 3-propanediol bicarbamates and 3-hydroxypropyl carbamates 
(Figure 1)  (Ludwig et al., 1969).  
          Compounds of interest were 2-substituted 1, 3-propanediol bicarbamates. A total of 5-7 
carbon atoms at the 2-position had the greatest muscle relaxing properties. An aryl group 
reduces muscle relaxing properties, while a methyl and a phenyl group has an enhanced anti-
convulsant activity and reduced muscle relaxing properties. N-Substituted compounds have 
also shown interesting properties. Replacement of one of N-hydrogen of the carbamate has 
yielded a number of compounds with interesting muscle relaxing properties. A prominent 
example is widely prescribed muscle relaxant carisoprodol or N-isopropyl-2-methyl-2-propyl-
1, 3-propanediol dicarbamate (Ludwig et al., 1969). 
          2-Substituted and N-substituted 3-hydroxypropyl carbamate, also show prominent 
muscle relaxing and anti-convulsant properties. 4-5 alkyl groups at position 2 gave good 
muscle relaxing property while an aromatic group at this position had good anti-convulsant 
property and attenuated muscle relaxant property. N-Substituted compounds also had 
prominent muscle relaxant and anti-convulsant compounds (Ludwig et al., 1969). 
          Our lab provides low cost methods for further evaluation of these drugs. A testing at 
GABAA subunits would enable us to have a quick prediction of therapeutic and abuse potentials 
of these drugs. We would start by generation of as many of the above promising ligands as 
possible. Each of the ligand would be tested for direct gating and allosteric modulatory effects 




of each ligand would be generated, along with a note on possible therapeutic as well as abuse 















































             In between carisoprodol and meprobamate, they have global effect on various subunit 
combinations of synaptic and extra-synaptic GABAA receptors. In addition to having effects 
on GABA mediated currents, they also have a direct-gating actions on all these native 
receptors. Meprobamate have also been shown to have partial inhibitory effect on NMDA 
receptors (Rho et al., 1997). In our lab and our colleague’s, we have shown carisoprodol also 
to have partial inhibitory effect on NMDA receptors, both in vitro in HEK-t transfected cells, 
as well as in animals trained to identify carisoprodol. Further clinical effects of carisoprodol 
also seem to affect serotonergic receptors (Bramness et al., 2005). Both the actions of 
carisoprodol and meprobamate on NMDA and 5 HT-3 receptors need to be further explored. 
Our knowledge of qualitative and quantitative aspects of effects of meprobamate and 
carisoprodol on various subunits of synaptic and extra-synaptic GABAA receptors, have 
enabled us to explain molecular basis of various clinical and toxic effects observed with the 
use and abuse of these drugs. Further research on the molecular mechanism of actions of these 
drugs (further exploration on GABAA receptors, NMDA and 5HT-3 receptors), would not only 
explain the clinical effects observed, but may also enable us to bring these drugs for new uses 
in select group of patients with specific needs. Our studies in lab could also prove to be 
important for drug development, as molecules with induced structural changes to have desired 
properties, can be quickly tested in cellular models, rather than time taking and costly animal 
models used in the initial development of these drugs. MEP and CSP would prove to be 
important drugs for blanket testing of reagents for a particularly useful action at an unknown 
potential therapeutic site of action or interaction with useful enzymes. Like amantadine, an 
anti-influenza drug also used as an anti-parkinsonism drug, their global action on receptors 
with varying physiological actions may prove to be an important property to test for actions on 
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